

Boat Tropanes

DOPAMINE TRANSPORTER IMAGING AGENTS

Insa

## FIELD OF THE INVENTION

The present invention relates to coordination complexes comprising a radiolabeled ligand with high binding affinity and good selectivity for the dopamine transporter (DAT). Such agents can be useful for the early diagnosis and treatment of neurodegenerative disorders.

## BACKGROUND OF THE INVENTION

The dopamine transporter (DAT) plays a critical role in physiological, pharmacological and pathological processes in brain. The transport system is a primary mechanism for terminating the effects of synaptic dopamine, thereby contributing to the maintenance of homeostasis in dopamine systems. It also appears to be a principal target of cocaine in the brain. (Kennedy and Hanbauer, *J. Neurochem.* 1983, 41, 172-178; Shoemaker et al., *Naunyn-Schmeideberg's Arch. Pharmacol.* 1985, 329, 227-235; Reith et al., *Biochem Pharmacol.* 1986, 35, 1123-1129; Ritz et al., *Science* 1987, 237, 1219-1223; Madras et al., *J. Pharmacol. Exp. Ther.* 1989a, 251, 131-141; Bergman et al., *J. Pharmacol. Exp. Ther.* 1989, 251, 150-155; Madras and Kaufman, *Synapse* 1994, 18, 261-275). Furthermore, the dopamine transporter may be a conduit for entry of neurotoxins into dopamine containing cells.

The striatum has the highest levels of dopamine terminals in the brain. A high density of DAT is localized on dopamine neurons in the striatum and appears to be a

marker for a number of physiological and pathological states. For example, in Parkinson's disease, dopamine is severely reduced and the depletion of DAT in the striatum has been an indicator for Parkinson's disease (Schoemaker et al., *Naunyn-Schmeideberg's Arch. Pharmacol.* 1985, 329, 227-235; Kaufman and Madras, *Synapse* 1991, 9, 43-49). Consequently, early or presymptomatic diagnosis of Parkinson's disease can be achieved by the quantitative measurement of DAT depletion in the striatum. (Kaufman and Madras, *Synapse* 1991, 9, 43-49). Simple and noninvasive methods of monitoring the DAT are quite important. Depletion could be measured by a noninvasive means such as brain imaging using a scintillation camera system and a suitable imaging agent (Frost et al., *Ann. Neurology* 1993, 34, 423-431; Hantraye et al., *Neuroreport* 1992, 3, 265-268). Imaging of the dopamine transporter also would enable the monitoring of progression of the disease and of reversal of the disease such as with therapies consisting of implants of dopamine neurons or drugs that retard progression of the disease.

Other neuropsychiatric disorders, including Tourette's Syndrome and Lesch Nyhan Syndrome and possibly Rett's syndrome, are also marked by changes in DAT density. The DAT also is the target of the most widely used drug for attention deficit disorder, methylphenidate. The capacity to monitor the transporter in persons suffering from this disorder can have diagnostic and therapeutic implications. Furthermore, an age-related decline in dopamine neurons can be reflected by a decline in the dopamine transporter (Kaufman and Madras, *Brain Res.* 1993, 611, 322-328; van Dyck et al., *J. Nucl. Med.* 1995, 36, 1175-1181) and may provide a view on dopamine deficits that lie outside the realm of neuropsychiatric diseases.

The density of the DAT in the brains of substance abusers has also been shown to deviate from that in normal brain. For example, the density is elevated in post-mortem tissues of cocaine abusers (Little et al., *Brain Res.* 1993, 628, 17-25). On the other hand, the density of the DAT in chronic nonviolent alcohol abusers is decreased markedly. (Tiihonen et al., *Nature Medicine* 1995, 1, 654-657). Brain imaging of substance abusers can be useful for understanding the pathological processes of cocaine and alcohol abuse and monitoring restoration of normal brain function during treatment.

Accordingly, a radiopharmaceutical that binds to the DAT can provide important clinical information to assist in the diagnosis and treatment of these various disease states.

In order to be effective as an imaging agent for the disorders described above, it must have a specific binding affinity and selectivity for the transporter being targeted, e.g. DAT. Brain imaging agents must also have blood brain barrier (BBB) permeability. Yet, it has been difficult to produce a metal chelate which can cross the blood brain barrier while still retaining binding affinity and selectivity for its receptor site. Therefore, it is very desirable to find a suitable agent that satisfies these criteria and will complex with a desired radionuclide, such as  $^{99m}\text{Tc}$ .

In addition, to be an effective imaging agent, a specific target:nontarget ratio is necessary. In the case of an agent selective for DAT one must take into account the

fact that the striatum, the region of the brain having the highest density of the dopamine transporter, also contains serotonin transporter (SET). The SET is normally present at one-tenth to one-fifteenth the concentration of the dopamine transporter. Imaging agents that bind very strongly to DAT sometimes also exhibit a degree of binding to SET. Although such a nontarget binding typically poses no serious problem in the imaging of normal brains due to the greater number of DAT compared to SET, under disease conditions in which DAT are selectively reduced (or in which SET may be selectively increased), binding to the SET may make it difficult to quantify DAT. Moreover, binding to SET in other brain regions such as the hypothalamus and thalamus can reduce striatal contrast and diminish accuracy in localizing and imaging the striatum. Therefore, the target to nontarget binding ratio of DAT:SET can be important. Presently, among the most effective compounds for viewing and quantifying the DAT are phenyltropane derivatives that are labelled with positron emitters, such as  $^{11}\text{C}$  and  $^{18}\text{F}$ , and gamma emitters, such as  $^{123}\text{I}$ .

The radionuclide, technetium-99m,  $^{99\text{m}}\text{Tc}$  ( $T_{1/2}$  6.9h, 140KeV gamma ray photon emission) is a preferred radionuclide for use in imaging because of its excellent physical decay properties and its chemistry. For example, its half-life of about 6 hours provides an excellent compromise between rate of decay and convenient time frame for an imaging study. Thus, it is much preferred to other radionuclides such as  $^{123}\text{I}$ , which has a substantially longer half life, or  $^{18}\text{F}$ , which has a substantially shorter half-life, and which are much more difficult to use. Its emission characteristics also make it easy to image. Further, it can be conveniently generated at the site of use.  $^{99\text{m}}\text{Tc}$  is currently the radionuclide of choice in diagnostic centers

around the world. It would be desirable to have a coordination complex with technetium for imaging DAT. Such a complex could be used for detecting conditions in which the DAT is useful as a marker.

5           However, a number of difficulties arise in the use of technetium for radioimaging agents because of its chemistry. For example,  $^{99m}\text{Tc}$  must typically be bound by a chelating agent. Consequently it is much more difficult to design and prepare a  $^{99m}\text{Tc}$  radioligand than it is to prepare a radioligand using other radionuclides such as  $^{123}\text{I}$ , which can be attached covalently to the ligand. The size of  
10           the chelating agent for technetium also can create problems when using this radionuclide in imaging agents. This can be an especially difficult problem when attempting to design receptor-based imaging agents using Tc.

15           Imaging agents being tested to determine their ability as diagnostic tools for neurodegenerative diseases typically are  $^{123}\text{I}$  labeled radioiodinated molecules. See, for example, RTI-55 (Boja, J.W., et al., *Eur. J. Pharmacol.* 1991, 194, 133-134; Kaufman and Madras, *Synapse*, 1992, 12, 99-111) or  $\beta$ -CIT (Neumeyer, J.L., et al., *Med. Chem.* 1991, 34, 3144-3146) and an iodoallyltropane, altropane (Elmaleh, D.R., et al., *US Patent No. 5,493,026*.

20           Although the tropane family of compounds are known to bind to the dopamine transporter, the addition of bulky chelating ligands for binding technetium or rhenium would be expected to affect potency and ability to cross the blood brain barrier of the resulting labeled complex. Kung, et al., in *Technetium and Rhenium in*

*Chemistry and Nuclear Medicine* 4, eds. M. Nicolini, G. Bandoli, U. Mazzi, Servizi Grafici Editoriali, Padua, 1995, report that a  $^{99}\text{Tc}$ -labelled  $\text{N}_2\text{S}_2$  ligand complexed with an arylpiperazine known to have selective binding to serotonin<sub>1A</sub> had only moderate binding affinity *in vitro* and failed to penetrate the intact blood-brain barrier.

5

It would be desirable to have a technetium or rhenium radio-labelled DAT imaging agent which is capable of crossing the blood brain barrier and has a high binding affinity and selectivity for the DAT.

10

#### SUMMARY OF THE INVENTION

15


The present invention provides radiopharmaceutical compounds that form coordination complexes with a technetium or rhenium radionuclide and that selectively bind to dopamine transporters, thereby providing novel radio labeled agents. Preferred such agents include radioimaging agents which are capable of crossing the blood brain barrier to image DAT in the brain.

20

The compounds of the present invention comprise a tropane compound linked through the N atom at the 8-position to a chelating ligand capable of complexing a technetium or rhenium radionuclide to produce a neutral labeled complex that selectively binds to the dopamine transporter. These compounds can be prepared as separate diastereoisomers as well as a mixture of diastereoisomers.

Tropane compounds useful in the practice of the present invention bind to the dopamine transporter. Preferred radiopharmaceutical compounds of the invention

can be represented by the following structural formula:



wherein  $R_1$  is  $\alpha$  or  $\beta$  and is selected from  $\text{COOR}^a$ ,  $\text{COR}^a$ , and  $\text{CON}(\text{CH}_3)\text{OR}^a$ ;

$R_2$  is  $\alpha$  or  $\beta$  and is selected from  $\text{C}_6\text{H}_4\text{X}$ ,  $\text{C}_6\text{H}_3\text{XY}$ ,  $\text{C}_{10}\text{H}_7\text{X}$ , and  $\text{C}_{10}\text{H}_6\text{XY}$ ;

$R^a$  is selected from  $\text{C}_1 - \text{C}_5$  alkyl, e.g. methyl, ethyl, propyl, isopropyl, etc.;

X and Y are independently selected from  $R^a$ , H, Br, Cl, I, F, OH, and  $\text{OCH}_3$ ;

L is  $-(\text{CH}_2)_n$  where n is an integer from 1 to 6, or  $-(\text{CH}_2)_n - (\text{aryl, arylalkyl, ethenyl or ethynyl}) - (\text{CH}_2)_m$  where the sum of n plus m is an integer from 1 to 6; and

Ch is a tridentate or tetradentate chelating ligand that forms a neutral complex with technetium or rhenium,

and further wherein the bond between  $\text{C}_2$  and  $\text{C}_3$  is either a single bond or a double bond.

Thus,  $R_1$  and  $R_2$  can be in the  $\alpha$  or  $\beta$  configuration. Further,  $R_1$  preferably can be

substituted at the  $\text{C}_2$  or  $\text{C}_4$  when the tropane has a 1R or 1S configuration,

respectively. The chelating ligand, if chiral, can be *syn* or *anti* with R, S, or RS.

The imaging agents of the present invention are useful for detecting tropane recognition sites including neuronal transporters such as the dopamine transporter.

5 For purposes of the present invention, a tropane recognition site is any receptor or transporter site that binds to the tropane compound. Thus, the compounds of this invention can be used as diagnostic agents, prognostic agents and therapeutic agents for neurodegenerative diseases.

10 The present invention also provides a method of using the coordination complex as an imaging agent for detecting neurodegenerative and neuropsychiatric disorders characterized by a change in density of DAT or dopamine neurons. For example, a method for detecting the change in DAT resulting from a neurodegenerative disease, such as Parkinson's disease, comprises injecting a labeled  
15 compound of the present invention in a dose effective amount for detecting DAT in the particular mammal and obtaining images of the labeled compound bound to DAT. Rhenium labeled compounds can also be useful for therapeutic treatments.

20 The present invention also provides kits for producing the compounds of the present invention labeled with technetium or rhenium. The kits typically comprise a sterile, non-pyrogenic container containing lyophilized compound and a reducing agent to form a complex of the compound with technetium or rhenium. The kits permit ready reconstitution and labeling with aqueous solutions containing the radionuclide, e.g. pertechnetate, preferably having a pH in the range of about 5 to



about 8.

#### BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 is an illustration of alternative general reaction schemes for linking a  
5  $N_2S_2$  chelating ligand to a nortropane analog and labeling with a metal "M", which can  
be technetium or rhenium.

FIG. 2 is an illustration of a general scheme for preparation of 2-carbomethoxy  
tropanes (Scheme 1) comprising an aryl octene in accord with the present invention  
10 and subsequent preparation of  $3\alpha$  and  $3\beta$  diastereomers thereof.

FIGs. 3 and 4 are illustrations of a general scheme for preparation of 2-  
ethylketo analogs (Schemes 2 and 3) of radiopharmaceutical compounds in accord  
with a preferred embodiment of the present invention.  
15

FIG. 5 is an illustration of a general scheme for preparation of 2-carboxamido  
 $3\alpha$ - or  $3\beta$ - aryl analogs (Scheme 4) of radiopharmaceutical compounds in accord with  
a preferred embodiment of the present invention.

20 FIG. 6 is an illustration of a general reaction scheme for preparation of 3-aryl-  
2-ethylketo-2,3-ene analogs (Scheme 5) of radiopharmaceutical compounds in accord  
with a preferred embodiment of the present invention.

FIG. 7 is an illustration of a general reaction scheme for preparation of 3-aryl-

2-carbomethoxy-2,3-ene analogs (Scheme 6) of radiopharmaceutical compounds in accord with a preferred embodiment of the present invention.

FIG. 8 is an illustration of a general scheme for converting the  $3\alpha$  and  $3\beta$  diastereomers of FIG. 2 to bistrityl protected  $N_2S_2$  tropanes and labeling with technetium or rhenium (Scheme 7).

FIG. 9 is an illustration of an alternative general reaction scheme for preparation of 3-aryl-2-ethylketo-2,3-ene analogs (Scheme 8) of radiopharmaceutical compounds in accord with a preferred embodiment of the present invention.

FIG. 10 is an illustration of a general reaction scheme for preparation of 3-naphthyl-2-carbomethoxy-2,3-ene and  $3\alpha$ -naphthyl or  $3\beta$ -naphthyl analogs (Scheme 9) of radiopharmaceutical compounds in accord with a preferred embodiment of the present invention.

FIG. 11 is a HPLC chromatogram of  $^{99m}\text{Tc}$  labeled O-1505T.

FIG. 12 is a HPLC chromatogram of  $^{99m}\text{Tc}$  labeled O-1508T.


FIG. 13 is a HPLC chromatogram of  $^{99m}\text{Tc}$  labeled O-1561T.

FIG. 14 is a HPLC chromatogram of  $^{99m}\text{Tc}$  labeled O-1560T.

## DETAILED DESCRIPTION OF THE INVENTION

The compounds of the present invention comprise a tropane compound or ligand that selectively binds to tropane recognition sites, e.g., neuron transporters such as the DAT. The tropane ligand is radiolabeled with a radioactive technetium or rhenium by a chelating ligand which is attached to the tropane ligand by a linker. The unlabeled compounds of this invention are schematically represented by the formula Ch-L-Tr, wherein Ch is the chelating ligand, L is the linker and Tr is the tropane ligand.

Tropane compounds or ligands useful in the practice of the present invention can generally be represented by formula II where  $R_1$  and  $R_2$  are defined as above and where  $R_1$  can also be substituted at the C<sub>4</sub> position of the tropane ring:




Any tropane compound of the general formula II is useful in the present invention so long as it binds to DAT. Examples of particularly useful tropanes are: 2-carbomethoxy-3-(4-fluorophenyl)-N-methyltropane ("WIN 35,428") (Clarke, R.L., et al., *J. Med. Chem.* 1973, 16, 1260-1267) which binds potently ( $IC_{50}=11.0$  nM) and with specificity to the DAT (Meltzer, P.C., et al., *J. Med. Chem.* 1993, 36, 855-862); 2-carbomethoxy-3-(3,4-dichlorophenyl)-N-methyltropane ("O-401";  $IC_{50}=1.09$  nM) (Meltzer, P.C., et al., *J. Med. Chem.* 1993, 36, 855-862). Tropane analogs that have a

3 $\alpha$ - group are of the boat configuration. Other tropanes having a 3 $\beta$ -oriented group are of the chair configuration.


Chelating ligands useful in the practice of the present invention comprise any tridentate or tetradentate ligand that binds technetium or rhenium to form a neutral complex. The chelating ligand is covalently attached to the linker L, as described below. Preferred chelating ligands contain a plurality of N or S atoms for complexing with the radionuclide.


Examples of suitable ligands are the N<sub>2</sub>S<sub>2</sub> compounds represented by the following structural formulas:




III

IV







V



VI



VII



VIII

wherein R, R<sup>6</sup>, and R<sup>10</sup> are each selected from hydrogen, substituted or unsubstituted lower alkyl, alkylR<sup>9</sup>, or -COR<sup>9</sup> where R<sup>9</sup> is selected from hydroxy, substituted lower alkoxy, substituted or unsubstituted amino, glycine ester, halide (chloro, bromo, iodo) or OR (OR is a leaving group such as mesylate, triflate, or tosylate) or an activated leaving group; R<sup>1</sup> is selected from hydrogen, or substituted or unsubstituted lower alkyl; R<sup>2</sup> and R<sup>3</sup> are each selected from hydrogen or a thiol protecting group, or an inter or intramolecular disulfide; and R<sup>4</sup>, R<sup>5</sup>, R<sup>7</sup> and R<sup>8</sup> are each selected from hydrogen or lower alkyl.

When R, R<sup>6</sup> or R<sup>10</sup> is a carboxylic acid derivative, R<sup>9</sup> can be an activated leaving group. For purposes of this invention the leaving group R<sup>9</sup> is defined such that (compound)-COR<sup>9</sup> is an acylating agent. Examples of activated leaving groups suitable for the practice of this invention include, for example: halide; substituted or unsubstituted aryloxy groups such as phenoxy, pentachlorophenoxy, etc.; oxyheterocyclic groups such as N-oxy-succinimido, etc.; mercapto; lower alkylthio; arylthio; oxyphosphonium; and other groups known to those skilled in the art to be useful as leaving groups.

R<sup>2</sup> and R<sup>3</sup> can be hydrogen or any known thiol protecting group. Examples of such groups include lower alkylaminocarbonyl such as ethylaminocarbonyl, lower alkanoylaminomethyl, aroylaminomethyl, t-butyl, acetamidomethyl, arylmethyl such as triphenylmethyl (trityl) and diphenylmethyl, aroyl such as benzoyl, aryloxycarbonyl such as phenoxycarbonyl, arylloweralkoxycarbonyl, preferably arylmethoxycarbonyl,

benzyloxycarbonyl, and lower alkoxycarbonyl such as t-butoxycarbonyl. Preferred thiol protecting groups include trityl, t-butyl, diphenylmethyl, acetamidomethyl and benzoyl and an inter or intramolecular disulfide.




5       The term "lower alkyl" when used herein designates aliphatic saturated branched or straight chain hydrocarbon monovalent substituents containing from 1 to 6 carbon atoms such as methyl, ethyl, isopropyl, n-propyl, n-butyl, etc., more preferably 1 to 4 carbons. The term "lower alkoxy" designates lower alkoxy substituents containing from 1 to 6 carbon atoms such as methoxy, ethoxy, isopropoxy, etc., more preferably 1 to 4 carbon atoms.

10       The terms substituted lower alkyl or substituted lower alkoxy when used herein include alkyl and alkoxy groups substituted with halide, hydroxy, carboxylic acid, or carboxamide groups, etc. such as, for example,  $-\text{CH}_2\text{OH}$ ,  $-\text{CH}_2\text{CH}_2\text{COOH}$ ,  $-\text{CH}_2\text{CONH}_2$ ,  $-\text{OCH}_2\text{CH}_2\text{OH}$ ,  $-\text{OCH}_2\text{COOH}$ ,  $-\text{OCH}_2\text{CH}_2\text{CONH}_2$ , etc.


15       The term substituted amino when used herein includes such groups mono or di and tri-substituted with lower alkyl, and  $-\text{NH}_3^+$  or mono, di and tri-substituted ammonium groups substituted with lower alkyl with a pharmacologically suitable anion.

20       The term glycine ester as used herein means the lower alkyl esters of glycine, preferably the methyl and ethyl esters.


These chelating ligands can be complexed with a radionuclide, e.g., technetium, to form the following complexes:








XII



XIII



XIV

where the  $R$  groups are defined as above.

Preferred embodiments of the invention use chelating ligands that are formed from monoaminomonoamide compounds having structures of formula V, VI or VII, e.g., *N*-{2-((2-((triphenylmethyl)-thio)-ethyl)amino)acetyl)-*S*-(triphenylmethyl)-2-aminoethanethiol ("MAMA").

5

Any organic linker having a backbone chain length of 1 to about 6 carbon atoms can be used to attach the chelating ligand, typically through its nitrogen, sulfur, R, R<sup>1</sup> or R<sup>6</sup>, to the 8-nitrogen atom of the tropane ligand (which binds the dopamine transporter). Examples of linkers include -(CH<sub>2</sub>)<sub>n</sub> where n is an integer from 1 to 6, or -(CH<sub>2</sub>)<sub>n</sub> - (aryl, arylalkyl, ethenyl or ethynyl) - (CH<sub>2</sub>)<sub>m</sub> where the sum of n plus m is an integer from 1 to 6.

10

Preferred radiolabeled compounds of the present invention cross the blood brain barrier and exhibit desired target:non-target specificity. Preferably, the selectivity ratio of binding (DAT:SET) is about 30 or more, more preferably 50 or more. Thus, they are useful as brain imaging agents, for example, for imaging DAT.

15

The tropane ligands can be linked to the chelating ligand by an initial conversion to nortropanes. Syntheses of nortropanes are known in the art, for example, as disclosed in Meltzer, P.C., et al., *J. Med. Chem.* 1993, 36, 855-862; Meltzer, P.C., et al., *J. Med. Chem.* 1994, 37, 2001-2010 (the disclosure of which is incorporated herein by reference). Tropanes can be synthesized from tropinone or cocaine by techniques known in the art. Synthesis of the nortropanes can then be achieved by N-demethylation of the tropane, which can be readily accomplished by

20

various methods known in the art, e.g., with  $\alpha$  - chloroethyl chloro formate (ACE-Cl).

The chelating ligand is preferably prepared separately and, then, either attached to the nortropane and metallated, or metallated first followed by attachment to the appropriate nortropane. When the radiolabeled compounds of the invention are required to cross the blood brain barrier, the chelating ligands useful in the present invention form neutral complexes with the radionuclide and are lipid soluble.

Chelating ligands that form neutral  $^{99m}\text{Tc(V)}$  complexes which are useful in the present invention include a substituted oxime (Loberg, M.D., et al., *J. Nucl. Med.* 1979, 20, 1181-1188),  $\text{N}_2\text{S}_2$  compounds (Davison, A., et al., *Inorg. Chem.* 1981, 20, 1629-1632; Davison, A., et al., *J. Nucl. Med.* 1979, 20, 641 (abstr)), bisaminoethanethiol ("BAT") (Kung, H.F., et al., *J. Med. Chem.* 1985, 28, 1280-1284; Kung, H.F., et al., *J. Nucl. Med.* 1986, 27, 1051; Kung, H.F., et al., *J. Med. Chem.* 1989, 32, 433-437; Kung, H.F., et al., *J. Nucl. Med.* 1984, 25, 326-332; Francesconi, L.C., et al., *Inorg. Chem.* 1993, 32, 3114-3124), and diaminodithiol ("DADT") (Lever, S.Z., et al., *J. Nucl. Med.* 1985, 26, 1287-1294). Additional examples of useful chelating ligands include N,N'-bis(2-mercapto-1-methyl)-2-aminobenzylamine ("U-BAT") (Francesconi, L.C., et al., *J. Med. Chem.* 1994, 37, 3282-3288), propylene amine oximes ("HMPAO"), diamidodithiol ("DADS") (Rao, T.N., et al., *J. Am. Chem. Soc.* 1990, 112, 5798-5804; Stepniak-Biniakiewicz, D., et al., *J. Med. Chem.* 1992, 35, 274-279), phenylenediamine-thiol-thioether ("PhAT") (McBride, B.J., et al., *J. Med. Chem.* 1993, 36, 81-86), bis(mercaptoethyl)-2-aminoethylamine ("SNS") or bis(mercaptoethyl)-2-thioethylamine (Mastrostamatis, S.G., et al., *J. Med. Chem.* 1994, 37, 3212-3218), monoamine amide ("MAMA") (Gustavson, L.M., et al., *Tet. Lett.* 1991, 32, 5485-5488)

and *N*-(2-((2-((triphenylmethyl)thio)ethyl)amino)acetyl)-*S*-(triphenylmethyl)-2-aminoethanethiol ("MAMA") (O'Neil, J.P., et al., *Inorg. Chem.* 1994, 33, 319-323). For example, when MAMA' is attached to a lipophilic tropane by a linker in accord with the present invention, a neutral, moderately lipophilic and aqueous stable compound  
5 suitable for radiolabeling is formed.

Compounds of formula III and IV can be synthesized according to the methods described in U.S. Patent No. 4,673,562 which is incorporated herein by reference.

Compounds of formula V can be synthesized by methods known in the art (see  
10 Fritzberg et al., *J. Nucl. Med.* 1981, 22, 258-263). Compounds of formula VI can also be synthesized by methods known in the art. (See O'Neil, J.P., et al., *Inorg. Chem.* 1994, 33, 319-323).

Radiolabeled complexes of the present invention can be prepared via three  
15 general preparation procedures as outlined in the General Scheme (FIG. 1). The general preparation scheme exemplifies the use of trityl protecting groups for the sulfhydryls, however, other protecting groups that are known to be useful for sulfhydryl protection can also be used such as, for example, lower alkylaminocarbonyl such as ethylaminocarbonyl, lower alkanoylaminomethyl, arylaminomethyl, *t*-butyl, acetamidomethyl, arylmethyl such as triphenylmethyl(trityl) and diphenylmethyl, aryl  
20 such as benzoyl, aryloxycarbonyl such as phenoxycarbonyl, aryl loweralkoxycarbonyl, preferably arylmethoxycarbonyl such as benzyloxycarbonyl, and lower alkoxycarbonyl such as *t*-butoxycarbonyl. Preferred sulfhydryl protecting groups include trityl, *t*-butyl, diphenylmethyl, acetamidomethyl, disulfide and benzoyl.

The compounds of the invention can be prepared by known means based upon the present disclosure. For example, starting with an appropriate chelating ligand, such as an  $N_2S_2$  compound, illustrated in the general scheme in FIG. 1 as *N*-{2-((2-  
5 ((triphenylmethyl)thio)ethyl)amino)acetyl}-*S*-(triphenylmethyl)-2-aminoethanethiol, (MAMA': Katzenellenbogen et al., *Inorg. Chem.*, 1994, 33, 319), the  $N_2S_2$  compound can be alkylated with either the haloalkyl triflate or the haloalkyl nortropane (prepared from the nortropane: Meltzer et al., *J. Med. Chem.*, 1993, 36, 855), producing the chloroalkyl (propyl shown) MAMA', or the tropanalkyl (propyl shown) MAMA',  
10 compounds, respectively. The chloroalkyl (propyl shown) MAMA' compound, can then be attached to a suitable nortropane to provide the tropanalkyl (propyl shown) MAMA' compounds, as shown. Alternatively, the chloroalkyl (propyl shown) MAMA', can be treated to incorporate a metal atom, preferably a radionuclide (such as  $^{99}Tc$ ,  $^{99m}Tc$ ,  $^{188}Re$  or  $^{186}Re$ ) to provide the M-labeled complex. The resulting complex can then be  
15 attached to a suitable nortropane to provide radiopharmaceutical compounds of the present invention, as shown.

Alternatively, the tropanalkyl (propyl shown) MAMA' compounds, can be treated to incorporate a radionuclide (such as  $^{99}Tc$ ,  $^{99m}Tc$ ,  $^{188}Re$  or  $^{186}Re$ ) to form  
20 radiopharmaceutical compounds of the present invention, as shown.

The compounds of the present invention can be either diastereoisomer as well as a mixture of both diastereomers. The diastereoisomers can be separated by column chromatography.

More specifically, alkylation of the  $N_2S_2$ , with haloalkyl triflate to produce the chloroalkyl (propyl shown) MAMA', can be used to prepare the linker which is used to bind the chelating ligand to the tropane ligand, which selectively binds the dopamine transporter. This alkylation step can be modified by those of ordinary skill in organic chemistry to create various linkers having a backbone chain length of 1 to about 6 carbon atoms, as described above.

Deprotection of the chloroalkyl compound can be accomplished by standard methods well known in the art, e.g., with  $H_2S/Hg(OAc)_2$  (O'Neil, J.P., et al., *Inorg. Chem.* 1994, 33, 319-323) or  $AgNO_3/Py$  (DiZio, J.P., et al., *Bioconj. Chem.* 1991, 2, 353-366), with TFA and phenol, or HBr in acetic acid (Zervas, L., et al., *J. Amer. Chem. Soc.* 1962, 84, 3887-3897) to result in the unprotected bithiol which can then be immediately treated with a solution of tin (II) chloride ( $SnCl_2$ ) and sodium perrhenate ( $Na_2ReO_7$ ) or an agent such as  $Na(^{99m}TcO_4)$ /stannous tartrate (Francesconi, L.C., et al., *Inorg. Chem.* 1993, 32, 3114-3124; Canney, D.J., et al., *J. Med. Chem.* 1993, 36, 1032-1040) to produce the labeled complexes. Purification of these chelates can be accomplished by flash chromatography as described by O'Neil (O'Neil, J.P., et al., *Inorg. Chem.* 1994, 33, 319-323). The chloroalkyl chelate, can then be reacted (O'Neil, J.P., et al., *Bioconj. Chem.* 1994, 5, 182-193) with the appropriate nortropane to provide the labeled coordination complexes of the present invention. Alkylation of nortropans can be accomplished by methods known in the art, e.g., acetonitrile ( $CH_3CN$ ), potassium iodide (KI) and potassium carbonate ( $K_2CO_3$ ). The use of strong base can cause epimerization of the carbomethoxy group at C-2, although sodium

carbonate in a solvent such as dimethyl formamide (DMF) can yield alkylated products in reasonable yield.

These compounds can be prepared either as free bases or as a pharmacologically active salt thereof such as hydrochloride, tartrate, sulfate, naphthalene-1,5-disulfonate or the like.

Reaction schemes for preparation of various classes of compounds of the present invention are described with reference to the drawings. In Scheme 1, as illustrated in FIG. 2, Keto ester **1** {Meltzer et al., *J. Med. Chem.*, 1994, **37**, 2001} is converted to the enol triflate **2** by reaction with N-phenyltrifluoromethanesulfonimide and sodium bis(trimethylsilyl)amide in tetrahydrofuran. The enol triflate **2** is then coupled with the appropriate commercial or preformed arylboronic acids by Suzuki coupling in diethoxymethane in the presence of lithium chloride, sodium carbonate and tris(dibenzylideneacetone)dipalladium(0) to provide aryl octenes **3** in excellent yield.

Reduction of the octenes **3** with samarium iodide in tetrahydrofuran/methanol at low temperature (-78 °C) provides a mixture of the 3 $\beta$ - and 3 $\alpha$ - diastereomers, **4** and **12** respectively. These diastereomers are readily separated by flash column chromatography.

In Scheme 7, as illustrated in FIG. 8, the 3 $\beta$ - and 3 $\alpha$ - diastereomers **4** and **12** are then treated similarly in their conversion to the bistrityl protected N<sub>2</sub>S<sub>2</sub> tropanes

**33** and **36** respectively and thence to the rhenium analogs **34R** and **37R** and the technetium analogs **34T** and **37T**. Thus, the tropanes are N-dealkylated by treatment with ACE-chloride {Meltzer et al., *J. Med. Chem.*, 1993, **36**, 855} to provide the nortropanes **32** and **35**. Introduction of the N<sub>2</sub>S<sub>2</sub> protected, ligand is then achieved  
5 by reaction of the nortropanes with the preformed N-[[[2-[2-(triphenylmethyl)thio]-ethyl](N'-3'-chloropropyl)amino]acetyl]-S-(triphenylmethyl)-2-aminoethanethiol (MAMA'-Cl){Meltzer et al. *J. Med. Chem.*, **40**, 1835, 1997} in the presence of potassium iodide and potassium carbonate. Rhenium can then be introduced upon reaction with tin (II) chloride in 0.05 M HCl, followed by sodium perrhenate in 0.05 M HCl.  
10 The product is purified by silica gel column chromatography and obtained as a mixture of diastereomers. An alternative approach utilizes N-alkylation of the nortropanes with preformed N-[(2-((3'-chloropropyl)(2-mercaptoethyl)amino)acetyl)-2-aminoethane-thiolato]rhenium (V) oxide {Meltzer et al. *J. Med. Chem.*, **40**, 1835, 1997}. Both diastereomers of the metal chelate are prepared.

15  
In Schemes 2 and 3, as illustrated in FIGs. 3 and 4, the 2-ethylketo analogs in both the 3 $\alpha$ - and 3 $\beta$ - series are prepared as shown. This discussion exemplifies the 3 $\beta$ -diastereomer, as illustrated in FIG. 3. The 3 $\beta$ -diastereomer **4** is hydrolyzed in dioxane/water or with lithium hydroxide to provide the acid, **5** which is converted to  
20 the amide through conversion to the acid chloride with oxalyl chloride and then reaction with (MeO)MeNH.HCl to provide **6**. Further reaction with alkyl Grignard at low temperature provides the desired ethyl or alkyl ketone **7**. The alkyl ketone **7** can be made alternatively by reaction of the ester-tropane (**4** or **12**) with the appropriate alkyl-Grignard-(ethylmagnesium bromide in this case) (Ref: I. Kikkawa and T. Vorifuji,



*Synthesis* (1980), p. 877). Demethylation is by standard treatment with ACE-Cl to obtain **8**. The chelating unit is attached by reaction of **8** with MAMA'-Cl in the presence of a base such as potassium carbonate or potassium bicarbonate and potassium iodide. Insertion of rhenium to provide **10** or technetium to provide **11** is accomplished with sodium perrhenate under reductive conditions, of the technetium heptogluconate. Both diastereomers of the metal chelate can be prepared in a similar manner. As seen by comparing Schemes 2 and 3, the 3 $\alpha$ - diastereomer of the tropane is prepared in a similar manner.

In Scheme 4, as illustrated in FIG. 5, the 2-carboxamide analogs **22** and **22A** are prepared from **14** by N-demethylation with ACE-Cl as described earlier. Attachment of the MAMA' group and insertion of the metal (rhenium or technetium) is conducted as described earlier for Schemes 2 and 3.

In Scheme 5, as illustrated in FIG. 6, the 2-ethylketo trop-2-ene analogs are prepared as shown in the scheme. Thus, ester **3** is hydrolyzed in dioxane/water or with lithium hydroxide to provide the acid **23** which is converted to the amide through conversion to the acid chloride with oxalyl chloride and then reaction with (MeO)MeNH.HCl to provide **24**. Further reaction with alkyl Grignard at low temperature provides the desired ethyl or alkyl ketone **25**. The alkyl ketone **25** can be formed alternatively by reaction of the ester tropene (**3**) with the appropriate alkyl-Grignard-(ethylmagnesium bromide) (Ref: I. Kikkawa and T. Vorifuji, *Synthesis* (1980), p. 877). Demethylation is by standard treatment with ACE-Cl to obtain **26**. The chelating unit is attached by reaction of **26** with MAMA'-Cl in the presence of a base

such as potassium carbonate or potassium bicarbonate and potassium iodide. Insertion of rhenium or technetium to provide **28** is accomplished with sodium perrhenate under reductive conditions of the technetium heptogluconate. Both diastereomers of the metal chelate **28** are prepared.

5  
In Scheme 6, as illustrated in FIG. 7, the 2-carbomethoxy trop-2-ene analogs are prepared as shown in the scheme. Demethylation of compound **3** is by standard treatment with ACE-Cl to obtain compound **29**. The chelating unit is attached by reaction of compound **30** with MAMA'-Cl in the presence of a base such as potassium carbonate or potassium bicarbonate and potassium iodide. Insertion of rhenium or  
10 technetium to provide compound **31** is accomplished with sodium perrhenate under reductive conditions, of the technetium heptogluconate. Both diastereomers of the metal chelate **31** are prepared.

15  
In Scheme 8, as illustrated in FIG. 9, the 2-ethylketo trop-2-ene analogs are prepared as shown in the scheme. Thus, compound **3** is reduced with LAH and reoxidized to obtain the aldehyde **39**. Reaction of the aldehyde with ethyl lithium or ethyl Grignard provides the alcohol **40** which is oxidized once again to obtain the ethyl ketone **26**. Compounds **27** and **28** are then obtained as above.

20  
In Scheme 9, as illustrated in FIG. 10, the 3-naphthyl trop-2-ene and 3 $\alpha$ - and 3 $\beta$ -tropanes are obtained by similar chemistry to that described earlier. Thus, the trop-2-ene **38** is N-demethylated with ACE-Cl and the MAMA' is attached to provide compound **40**. Rhenium or technetium are inserted as before to obtain the

diastereomers **41**. Alternatively, compound **38** is first reduced with samarium iodide to obtain both the boat and chair configured compounds **43** and **42**. The same sequence of reactions then provides the rhenium and technetium diastereomers of both the 3 $\alpha$ - and 3 $\beta$ -tropanes, **49** and **48**.

5

The technetium or rhenium radionuclide complexes of this invention can be formed by reacting suitable precursor compounds with either pertechnetate or perrhenate in the presence of a suitable reducing agent in a conventional manner. For example, the compound can be dissolved in a suitable solvent with a reducing agent and then pertechnetate added. The mixture is then heated for a suitable length of time to complete the reaction. Typically, heating in a boiling water bath for about 10 minutes has been found sufficient to obtain very good yields of the radionuclide complex. To form rhenium complexes, (Ph<sub>3</sub>P)<sub>2</sub>ReOCl<sub>3</sub> is added in the presence of basic (NaOAc) methanol. Examples of reducing agents useful in the practice of this invention include stannous salts such as stannous chloride, sodium dithionite, and ferrous salts such as ferrous sulfate.

10

15

Rhenium behaves similarly to Tc. Thus, N<sub>2</sub>S<sub>2</sub> complexes of Re or Tc are equally stable. Both metals form square pyramidal complexes with N<sub>2</sub>S<sub>2</sub> ligands.

20

(Francesconi, L.C., et al., *Inorg. Chem.* 1993, 32, 3114-3124). Rhenium is a preferred metal for use in studies which do not require the presence of a short half life radiolabel. For complexes with both technetium and rhenium, the oxygen occupies an apical position, therefore both syn and anti-isomers of the metal complexes are possible. The biological activity of Tc and Re chelates are generally similar. (O'Neil,

J.P., et al., *Bioconjugate Chem.* 1994, 5, 182-193).  $^{99m}\text{Tc}$  is a preferred radionuclide for use as an imaging agent. Rhenium is an excellent model for  $^{99m}\text{Tc}$  and is also useful as a therapeutic agent.

5 A preferred method for introducing the technetium radionuclide was by reaction of the bistrityl protected compounds in presence of anhydrous trifluoroacetic acid and then triethylsilane. A portion of the aqueous solution thus obtained was then incubated with  $^{99m}\text{Tc}$ -glucoheptonate solution (Glucoscan kits from Du Pont, Billerica, MA). HPLC separation on a C8 reverse phase column equipped provides the  
10 major  $^{99m}\text{Tc}$  labeled product which was reconstituted in sterile saline for injection.

The compounds of this invention are typically enantiomerically pure tropanes (either 1S or 1R configuration) attached by an achiral linker to a chiral chelating ligand. The chiral chelating ligand can be *cis* or *trans* with respect to the metal oxo  
15 and the linker, but is preferably *cis*. Each of the *cis* and *trans* chelating ligands exist as a pair of two enantiomers. By virtue of the chiral ligand which can exist in each of two enantiomeric forms, and a chiral tropane, each of the whole molecules exists as diastereoisomers. Radiopharmaceutical compositions of the present invention include the separate diastereoisomers of each, as well as mixtures of diastereomeric pairs.

20

The compounds of the present invention preferably have a target:nontarget ratio, such as a DAT:SET selectivity ratio of greater than 10, and preferably at least 30, to minimize binding of trace levels of the drug to the nontarget, e.g., serotonin transporter.

The present invention also provides pharmaceutical kits, preferably comprising the compounds of formula I with a reducing agent in lyophilized form in a pyrogen-free, sterilized container or vial. In this form the lyophilized composition can be readily reconstituted by adding only water, saline, or a buffer preferably having a pH in the range of 5 to 8, more preferably physiological pH. If technetium is the metal to be used as the radionuclide, pertechnetate solution from a technetium generator can be used for reconstitution.

In general, the radiopharmaceutical preparation kit comprises a sterilized unit dose (or multidose) vial containing the purified compound of formula I and a reducing agent for technetium, preferably lyophilized. Each dose should consist of a sufficient amount of compound and reducing agent to prepare the required dose for imaging, normally about 5 to about 30 mCi of  $^{99m}\text{Tc}$  depending upon body weight of the mammal to be imaged. In use, the technetium, preferably as  $^{99m}\text{Tc}$ -pertechnetate in saline, is injected aseptically into the vial and the mixture reacted for a sufficient time to form the labeled complex. After reaction, typically, the resulting radiopharmaceutical is ready for use.

To image a desired target, a radiopharmaceutical preparation in accord with this invention having an effective dose of radioactivity for the particular mammal is prepared in a suitable pharmacological carrier, such as normal saline. Preferably, the radiopharmaceutical preparation is injected intravenously into the mammal. The target, e.g., the brain, is then imaged by positioning the mammal under a gamma

camera or other suitable device.

In order to obtain high quality images, the radiochemical yield of bound technetium in the desired radiopharmaceutical should preferably be greater than 70% after reconstituting the lyophilized mixture and labelling. Lower yields may result in poorer image quality and undesirable purification steps may be required to produce high quality images.

This invention will be illustrated further by the following examples. These examples are not intended to limit the scope of the claimed invention in any manner.

The final compounds were characterized and their purity analyzed prior to biological evaluation. High field nuclear magnetic resonance (NMR) spectra were measured as well as low and high resolution mass spectra (MS) and infrared spectra (IR). Elemental analyses, thin layer chromatography (TLC) and/or high performance liquid chromatography (HPLC) were used as a measure of purity. A purity of >98% was obtained before biological evaluation of these compounds was undertaken.

In the following examples, NMR spectra were recorded on either a Bruker 100, a Varian XL 400, or a Bruker 300, or a Jeol 300 NMR spectrometer. TMS was used as internal standard. Melting points are uncorrected and were measured on a Gallenkamp melting point apparatus. Optical rotations were measured at the sodium D line at 21°C using a JASCO DIP 320 polarimeter (1dcm cell). Thin layer chromatography (TLC) was carried out on Baker Si 250F plates. Visualization was

accomplished with either iodine vapor, UV exposure or treatment with phosphomolybdic acid (PMA). Preparative TLC was carried out on Analtech uniplates Silica Gel GF 2000 microns. Flash chromatography was carried out on Baker Silica Gel 40 M (SiO<sub>2</sub>). Elemental Analyses were performed by Atlantic Microlab, Atlanta, GA. A Beckman 1801 Scintillation Counter was used for scintillation spectrometry. 0.1% Bovine Serum Albumin and (-)-Cocaine were purchased from Sigma Chemicals. All reactions were conducted under an atmosphere of dry nitrogen.

[<sup>3</sup>H]WIN 35,428 and 2 $\beta$ -carbomethoxy-3 $\beta$ -(4-fluorophenyl)-N-[<sup>3</sup>H]methyltropane (79.4-87.0 Ci/mmol), and [<sup>3</sup>H]citalopram (86.8 Ci/mmol) were purchased from DuPont-New England Nuclear (Boston, MA). TEA is triethylamine. (-)-Cocaine hydrochloride for the pharmacological studies was donated by the National Institute on Drug Abuse [NIDA]. Fluoxetine was donated by E. Lilly & Co. HPLC analyses were carried out on a Waters 510 system with detection at 254 nm on a Waters 8 mm, C-18, 10 m reverse phase column. Pd<sub>2</sub>dba<sub>3</sub> is trisdibenzylideneacetone dipalladium, TFA is trifluoroacetic acid, THF is tetrahydrofuran, EtOAc is ethyl acetate.

EXAMPLE 1: (1*R*)-2-(Methoxycarbonyl)-3-[[[(trifluoromethyl)sulfonyl]oxy]-trop-2-ene (Compound 2, FIG. 2)

(1*R*)-(-)-2-Methoxycarbonyl-3-tropinone, **1** {Meltzer et al., *J. Med. Chem.*, 1994, **37**, 2001}(1 g, 5.07 mmol) was dissolved in anhydrous THF (20 mL) and the resulting solution cooled to -78 °C. A solution of sodium bistrimethylsilylamide (1 M, 5.58 mL, 5.58 mmol) was then added to the solution slowly. After 30 min, N-phenyltrifluoro-

methane sulfonamide (1.94 g, 5.43 mmol) was added. The resulting solution stirred for a further 45 min at -78 °C and then allowed to attain room temperature and stirred at room temperature for 2h. All solvent was evaporated and the residue pumped to dryness. Column chromatography was performed on the residue (SiO<sub>2</sub> 60 g; 2%-16% methanol in ethyl acetate) and gave 1.62 g (97%) of a yellow oil which crystallized on standing.

R<sub>f</sub> 0.65 (10% MeOH/EtOAc). <sup>1</sup>H-NMR (CDCl<sub>3</sub>) δ 1.58 (m, 1H), 1.97 (m, 2H), 2.1-2.2 (m, 2H), 2.39 (s, 3H). 2.84 (dd, J=18, 4Hz, 1H), 3.42 (t, J=6Hz, 1 H), 3.8 (s, 3H), 3.92 (d, J=5Hz, 1H).

EXAMPLE 2: (1*R*)-N-Methyl-2-methoxycarbonyl-3-(3,4-dichlorophenyl)-8-azabicyclo[3.2.1]oct-2-ene (Compound 3, FIG. 2)

(1*R*)-2-Methoxycarbonyl-3-[[[(trifluoromethyl)sulfonyl]oxy] tropene 2 (620 mg, 1.88 mmol), LiCl (171 mg, 4.03 mmol), Pd<sub>2</sub>dba<sub>3</sub> (69 mg, 0.075 mmol), aq. Na<sub>2</sub>CO<sub>3</sub> (2.0 M, 2 mL), diethoxymethane (6.2 mL) were all charged to a flask and stirred vigorously. To this solution was added 3,4-dichlorophenyl boronic acid (474 mg, 2.49 mmol). The reaction was then brought to reflux for 2h and filtered through celite. The cake was washed with ether and the organic solution was washed with concentrated NH<sub>4</sub>OH. The washed solvent was dried with K<sub>2</sub>CO<sub>3</sub>, filtered, and evaporated. The residue was charged to a column (SiO<sub>2</sub>, 60 g, eluted with 5-6% Et<sub>3</sub>N/EtOAc) and gave 512 mg (83%) of a yellow oil which solidified upon standing.



R<sub>f</sub> 0.56 (10% Et<sub>3</sub>N/EtOAc). IR (KBr) 2941, 1724, 1460, 1418, 1333, 1250, 1212, 1124 cm<sup>-1</sup>. <sup>1</sup>H-NMR (CDCl<sub>3</sub>) δ 1.61 (m, 1H), 1.9-2.05 (m, 2H), 2.1-2.3 (m, 2H), 2.43 (s, 3H), 2.76 (dd, J=19, 4.7 Hz, 1H), 3.36 (t, J=4.9Hz, 1H), 3.52 (s, 3H), 3.86 (d, J=5.5 Hz, 1H), 6.96 (dd, J=8.3, 1.9 Hz, 1H), 7.2 (d, J=2.2Hz, 1H), 7.37 (d, J=8.2 Hz, 1H). Elemental analysis: calculated C, 58.91, H, 5.25, N, 4.29; found C, 58.84, H, 5.24, N, 4.24.

EXAMPLE 3: (1*R*)-*N*-Methyl-2β-methoxycarbonyl-3β-(3,4-dichlorophenyl)-8-azabicyclo[3.2.1]octane (Compound **4** (R=3,4-Cl<sub>2</sub>), FIG. 2),  
and  
(1*R*)-*N*-Methyl-2β-methoxycarbonyl-3α-(3,4-dichlorophenyl)-8-azabicyclo[3.2.1]octane (Compound **12** (R=3,4-Cl<sub>2</sub>), FIG. 2)

To (1*R*)-*N*-Methyl-2-methoxycarbonyl-3-(3,4-dichlorophenyl)-8-azabicyclo[3.2.1]oct-2-ene, **3** (4 g, 12.3 mmol) in THF (43 mL) at -78 °C was added Sml<sub>2</sub> solution (0.1 M in THF, 400 mL, 40 mmol) dropwise. After 30 min at -78 °C, MeOH (140 mL) was added and the resulting solution stirred at -78 °C for a further 1h. The reaction was then quenched with TFA (28 mL) and water (285 mL), the cold bath was removed and the solution allowed to attain room temperature. The reaction was then made basic with NH<sub>4</sub>OH and diluted with ether and filtered through celite. The filter cake was washed with ether and all the organic phases were combined and washed with a sodium thiosulfate solution and then a brine solution. After drying with Na<sub>2</sub>SO<sub>4</sub> the solution was filtered and concentrated and gave 3.8 g of the crude products. The title compounds **4** and **12** were isolated by column chromatography (SiO<sub>2</sub>, 10 g; 2.5% EtOH in CHCl<sub>3</sub>). Compound **12** was isolated as colorless crystals

(1.15 g, 29%).

Mp. 89-91 °C. R<sub>f</sub> 0.64 (1% NH<sub>4</sub>OH/EtOAc). <sup>1</sup>H-NMR (CDCl<sub>3</sub>) δ 1.28 (ddd, J=1.6, 10.4, 14, 1H), 1.4-1.6 (m, 2H), 2.23 (s, 3H), 2.05-2.3 (m, 2H), 2.35-2.5 (m, 2H), 3.2-3.47 (m, 3H), 3.59 (s, 3H), 7.04 (dd, J=2.2, 8.2Hz, 1H), 7.27 (d, J = 2.2 Hz, 1H), 7.30 (d, J=8.2 Hz, 1H). Elemental analysis: calculated (0.1 C<sub>6</sub>H<sub>14</sub>) C, 59.18, H, 6.10, N, 4.16, Cl, 21.05; found C, 59.11, H, 5.90, N, 4.08, Cl, 21.01.

Compound **4** (R=3,4-Cl<sub>2</sub>) (Meltzer et al., *J. Med. Chem.*, 1993, **36**, 855-862) was isolated as a yellow solid (1.04 g, 26%).

Mp. 82.5-83.5 °C. R<sub>f</sub> 0.43 (IPA/Et<sub>2</sub>O/pentane; 3/30/67); <sup>1</sup>H NMR (400MHz, CDCl<sub>3</sub>) δ 1.6-1.7 (m, 3H), 2.0-2.1 (m, 2H), 2.21 (s, 3H), 2.50 (ddd, 1H, H-4), 2.86(m, 1H), 2.92 (m, 1H), 3.33 (m, 1H, H-5), 3.52 (s, 3H), 3.55 (m, 1H), 7.07-7.32 (m, 3H). [α]<sub>D</sub><sup>21</sup> -27.0° (c=1, CH<sub>3</sub>OH). Anal. (C<sub>16</sub>H<sub>19</sub>NO<sub>2</sub>Cl<sub>2</sub>) C, H, N, Cl.

EXAMPLE 4: (1*R*)-N-Methyl-2β-methoxycarbonyl-3β-(4-fluorophenyl)-8-azabicyclo[3.2.1]octane (Compound **4** (R=4-F), FIG. 2) and

(1*R*)-N-Methyl-2β-methoxycarbonyl-3α-(4-fluorophenyl)-8-azabicyclo[3.2.1]octane (Compound **12** (R=4-F), FIG. 2; O-1204)

Using the same general procedure as described above for Example 3, except substituting (1*R*)-N-Methyl-2-methoxycarbonyl-3-(4-fluorophenyl)-8-aza-

bicyclo[3.2.1]oct-2-ene, **3**, compounds **4** and **12** (R=4-F) were obtained.

Compound **4** (R=4-F) : white solid; Mp 93-94 °C;

R<sub>f</sub> 0.42 (i-PrNH<sub>2</sub>:Et<sub>2</sub>O:pentane::5:30:65); <sup>1</sup>H-NMR (400 MHz, CDCl<sub>3</sub>) δ 1.57-1.75 (m, 3H), 2.0-2.2 (m, 2H), 2.23 (s, 3H), 2.54 (ddd, 1H), 2.84 (t, 1H), 2.95 (ddd 1H, J=5.3, 12.7 Hz), 3.36 (m, 1H), 3.50 (s, 3H), 3.55 (m, 1H), 6.9-7.25 (m, 4H). [α]<sub>D</sub><sup>21</sup> -45.6° (c=1, CH<sub>3</sub>OH). Anal. (C<sub>16</sub>H<sub>20</sub>NO<sub>2</sub>F) C, H, N.

Compound **12** (R=4-F) : colorless oil;

R<sub>f</sub> 0.5 (10% MeOH in EtOAc); Elemental analysis: calculated C, 69.29 , H, 7.27 , N, 5.05; found C, 69.35 , H, 7.26, N, 5.00; IR 2900, 1750, 1500 cm<sup>-1</sup>, <sup>1</sup>H-NMR (100 MHz, CDCl<sub>3</sub>) δ 1.1-1.8 (m, 4H), 1.9-2.6 (m, 3H), 2.25 (s, 3H), 3.1-3.7 (m, 3H), 3.59 (s, 3H), 6.8-7.3 (m, 4H).

EXAMPLE 5: 2β-Carboxy-3β-(4-fluorophenyl)tropane  
(Compound **5** (R=4-F), FIG. 3)

2β-Methoxycarbonyl-3β-(4-fluorophenyl)tropane (WIN 35,428), **4** (1.25 g, 4.54 mmol) was refluxed for 24 h in a 1:1 dioxane-water (80 mL) solution. The solvent was removed in vacuo and the residue was almost completely dissolved in CHCl<sub>3</sub> (275 mL). Remaining undissolved solid was filtered off, toluene (30 mL) was added, and the solution was reduced in vacuo by approximately 75%. After cooling the resulting white suspension in the freezer for 2 h, the white solid was removed by filtration and was washed with cold 1:1 CHCl<sub>3</sub>-toluene. The solid was pumped dry to yield the

product **5** as a white solid (1.11 g, 95%).

<sup>1</sup>H-NMR (CDCl<sub>3</sub>) δ 1.7-1.8 (m, 1H), 1.94 (dd, J=9 Hz, 2H) 2.24-2.34 (m, 2H), 2.25 (m, 3H), 2.57 (ddd, J=13.7 Hz, 1H), 2.62-2.68 (m, 1H), 3.16 (ddd, J=13 Hz, 1H), 3.5-3.6 (m, 2H), 6.8 (m, 2H), 7.18-7.24 (m, 2H).

EXAMPLE 6: 2β-Carboxy-3β-(3,4-dichlorophenyl)tropane  
(Compound **5** (R=3,4-Cl<sub>2</sub>), FIG. 3)

2β-Methoxycarbonyl-3β-(3,4-dichlorophenyl)tropane, **4** (1.14 g, 3.47 mmol) was dissolved in THF:MeOH (1:1; 46 mL) to which was added a solution of LiOH.H<sub>2</sub>O (153 mg) in water (11 mL). The solution was heated to reflux for 24h, cooled to 0 °C and neutralized (pH=7) with conc. HCl. Silica (1.75 g) was added directly to the solution and solvent was removed in vacuo. The material was purified by flash chromatography column (eluent 20% MeOH/CHCl<sub>3</sub> (900 mL) followed by 30% MeOH/CHCl<sub>3</sub> (2 L)). Fractions containing the product were collected and combined, evaporated in vacuo and the residue was dried at high vacuum. The product was obtained (310 mg; 28%).

R<sub>f</sub> 0.08 (30% MeOH/CHCl<sub>3</sub>); <sup>1</sup>H-NMR (CDCl<sub>3</sub>) δ 1.8-1.9 (m, 1H), 2.1-2.2 (m, 2H) 2.3-2.5 (m, 2H), 2.6-2.9 (m, 2H), 2.78 (s, 3H), 3.3-3.4 (m, 1H), 3.93 (m, 2H), 7.25 (dd, J=8.2 Hz, 2.2 Hz, 1H), 7.41 (d, J=8.2 Hz, 1H), 7.48 (d, J=2.2 Hz, 1H).

EXAMPLE 7: 2 $\beta$ -Methoxymethylcarbamoyl -3 $\beta$ -(4-fluorophenyl)tropane  
(Compound **6** (R=4-F), FIG. 3)

To a stirred suspension of the acid **5** (1.1 g) in anhydrous CH<sub>2</sub>Cl<sub>2</sub> (80 mL) containing DMF (50  $\mu$ L) was added oxalyl chloride (1 mL, 11.4 mmol) dropwise resulting in copious bubbling and dissolution of the suspension. The reaction was allowed to stir for 45 min during which time the solution became yellow. The solution was then reduced in vacuo and pumped at high vacuum overnight, care being taken to bleed nitrogen into the evacuated flask when transferring from the rotary to the pump.

To the acid chloride dissolved in CH<sub>2</sub>Cl<sub>2</sub> (80 mL) was added (MeO)MeNH HCl (450 mg; dried immediately prior to use over P<sub>2</sub>O<sub>5</sub> under high vacuum followed immediately by pyridine (1.1 mL). The reaction was allowed to stir for 1h and was partitioned across CHCl<sub>3</sub> (20 mL) and 2M Na<sub>2</sub>CO<sub>3</sub> (20 mL). The aqueous layer was extracted CHCl<sub>3</sub> (2 x 10 mL) and the combined organic extracts were dried over Na<sub>2</sub>SO<sub>4</sub>, filtered and reduced in vacuo to yield 1.09 g of a yellow solid. The crude product was dissolved in CH<sub>2</sub>Cl<sub>2</sub> and purified by flash chromatography (SiO<sub>2</sub>, 43 g; 20% hexanes/EtOAc, 5% Et<sub>3</sub>N). Product containing fractions were combined and concentrated to yield a light yellow solid **6** (960 mg; 75%).

Mp. 120.1-122.5 °C; R<sub>f</sub> 0.14 (25% hexanes /EtOAc, 5% TEA); Elemental analysis: calculated C, 66.65 , H, 7.57 , N, 9.14 ; found C, 66.78 , H, 7.63 , N, 9.01; IR (KBr) 2900, 1680, 1500 cm<sup>-1</sup>; <sup>1</sup>H-NMR (CDCl<sub>3</sub>)  $\delta$  1.5-1.8 (m, 3H), 2.0-2.3 (m, 2H), 2.24 (m, 3H), 2.79 (ddd, 1H), 3.0 (m, 1H), 3.05 (s, 3H), 3.1 (m, 1H), 3.4 (m, 1H), 3.47 (m, 1H),

3.57 (s, 3H), 6.9 (m, 2H), 7.25 (m, 2H).

EXAMPLE 8: 2β-Methoxymethylcarbamoyl-3β-(3,4-dichlorophenyl)tropane  
(Compound 6 (R=3,4-Cl<sub>2</sub>), FIG. 3)

5 To a stirred solution of 2β-carboxy-3β-(3,4-dichlorophenyl)tropane, **5** (300 mg, 9.55 mmol) in anh. CH<sub>2</sub>Cl<sub>2</sub> (30 mL) was added anh. DMF (40 μL) and oxalyl chloride (450 μL) dropwise. The solution was stirred at room temperature for 40 min. The solvent was removed in vacuo and the residue dried at high vacuum overnight.

10 To the dry residue was added methoxy methylamine hydrochloride (103 mg, 1.05 mmol). The flask was flushed with nitrogen and CH<sub>2</sub>Cl<sub>2</sub> (30 mL) was added by cannula followed immediately by pyridine (400 μL). The reaction was stirred for 2.5h. The resultant mixture was partitioned between CH<sub>2</sub>Cl<sub>2</sub> (40 mL) and 1M Na<sub>2</sub>CO<sub>3</sub> (25 mL). The aqueous layer was extracted with CHCl<sub>3</sub> and the combined organic extracts were dried and concentrated to yield a yellow solid (298 mg). The solid was purified  
15 on a chromatography column (eluent 50% EtOAc/hexane/5% Et<sub>3</sub>N). Like fractions were combined, solvent removed and the product dried at high vacuum to yield Compound **6** (39 mg; 11%).

R<sub>f</sub> 0.1 (50% EtOAc/hexane/5% Et<sub>3</sub>N); <sup>1</sup>H-NMR (CDCl<sub>3</sub>) δ 1.5-1.74 (m, 3H), 2.0-2.3

20 (m, 2H), 2.21 (m, 3H), 2.72 (ddd, 1H), 2.93 (m, 1H), 3.04 (s, 3H), 3.13 (m, 1H), 3.38 (m, 1H), 3.5 (m, 1H), 3.62 (s, 3H), 7.13 (dd, 1H), 7.30 (d, 1H), 7.31 (d, 1H).

EXAMPLE 9: 2 $\beta$ -(1-Propanoyl)-3 $\beta$ -(4-fluorophenyl)tropane

(Compound **7** (R=4-F), FIG. 3)

A solution of 2 $\beta$ -(N-methoxy-N-methylcarbamoyl)-3 $\beta$ -(4-fluorophenyl)-tropane, **6** (823 mg, 2.7 mmol) in THF (10 mL) was cooled to 0 °C and EtMgBr/Et<sub>2</sub>O (3M; 3 mL) was added dropwise over 4 min. The reaction was warmed to room temperature for 30 min and then heated to 65 °C for 45 min. The mixture was cooled to 0 °C and quenched by addition of ethereal HCl (3M). The resulting cloudy solution was basified with 2M Na<sub>2</sub>CO<sub>3</sub>. Ether (5 mL) was added and the layers separated and the aqueous layer washed with Et<sub>2</sub>O (1 x 10 mL) and CHCl<sub>3</sub> (2 x 10 mL). The combined organic extracts were dried over Na<sub>2</sub>SO<sub>4</sub>, filtered and concentrated. The product was purified by flash column chromatography (eluent 25% EtOAc/hexanes/5% TEA) to provide **7** (485 mg, 65 %).

R<sub>f</sub> 0.3 (20% EtOAc/hexanes/5% Et<sub>3</sub>N); mp 118-119.5 °C; Elemental analysis: calculated C, 74.15 , H, 8.05, N, 5.09; found C, 74.05, H, 8.09, N, 5.00. IR (KBr) 2900, 1710, 1500. 1250 cm<sup>-1</sup>; <sup>1</sup>H-NMR (CDCl<sub>3</sub>)  $\delta$  0.85 (t, 3H); 1.5-1.8 (m, 4H), 2.0-2.4 (m, 3H), 2.23 (m, 3H), 2.5-2.6 (m, 1H), 2.9-3.0 (m, 2H), 3.36 (m, 1H), 3.48 (m, 1H), 6.69 (m, 2H), 7.17 (m, 2H).

EXAMPLE 10: 2 $\beta$ -(1-Propanoyl)-3 $\beta$ -(3,4-dichlorophenyl)tropane

(Compound **7** (R=3,4-Cl<sub>2</sub>), FIG. 3)

A solution of 2 $\beta$ -methoxymethylcarbamoyl-3 $\beta$ -(3,4-dichlorophenyl), **6** (168 mg, 0.47 mmol) in THF (30 mL) was cooled to 0 °C and EtMgBr/Et<sub>2</sub>O (3M; 1 mL) was

added dropwise over 3 min. The reaction was warmed to room temperature for 60 min and then heated to reflux for 10 min. The mixture was cooled to room temperature and quenched by addition to ethereal HCl (3M, 20 mL). The resulting cloudy solution was basified with saturated aqueous NaHCO<sub>3</sub> and brought to pH=10 by addition of Na<sub>2</sub>CO<sub>3</sub>. Ether was added and the layers separated and the aqueous layer washed with Et<sub>2</sub>O (3 x 25 mL). The combined organic extracts were dried over Na<sub>2</sub>SO<sub>4</sub>, filtered and concentrated. The product (166 mg) was purified by flash column chromatography (eluent 30% EtOAc/hexanes/5% Et<sub>3</sub>N) to provide **7** (108 mg, 71%).

R<sub>f</sub> 0.32 (50% EtOAc/hexanes/5% Et<sub>3</sub>N); <sup>1</sup>H-NMR (CDCl<sub>3</sub>) δ 0.9 (t, 3H), 1.5-1.8 (m, 4H), 2.0-2.3 (m, 3H), 2.2 (m, 3H), 2.35-2.55 (m, 2H), 2.82-2.92 (m, 1H), 2.96 (m, 1H), 3.34 (m, 1H), 3.54 (m, 1H), 7.75 (dd, 1H), 7.27 (d, 1H), 7.29 (d, 1H).

EXAMPLE 11: 2β-(1-Propanoyl)-3β-(4-fluorophenyl)nortropane  
(Compound **8** (R=4-F), FIG. 3)

2β-(1-Propanoyl)-3β-(4-fluorophenyl)tropane, **7** (335 mg) was combined with 1-chloroethyl chloroformate (5 mL) and the solution was heated to reflux for 5h. The excess chloroformate was removed in vacuo and the residue was refluxed in methanol for 1.5h. The methanol was removed in vacuo and the residue was dissolved in CHCl<sub>3</sub> (15 mL) and shaken with 2M Na<sub>2</sub>CO<sub>3</sub>. The aqueous layer was extracted CHCl<sub>3</sub> (2 x 15 mL) and the combined organic extracts were dried (Na<sub>2</sub>SO<sub>4</sub>), filtered and concentrated to yield 369 mg. This residue was chromatographed (eluent: 100



mL EtOAc, 150 mL 5% Et<sub>3</sub>N/EtOAc, 100 mL 10% Et<sub>3</sub>N/EtOAc, 300 mL 20% Et<sub>3</sub>N/EtOAc, and 300 mL 30% Et<sub>3</sub>N/EtOAc). Like fractions were combined to yield **8** (104 mg, 33%).

5 R<sub>f</sub> 0.36 (10% Et<sub>3</sub>N/EtOAc); <sup>1</sup>H-NMR (CDCl<sub>3</sub>) δ 0.70 (t, 3H), 1.4-1.8 (m, 5H), 1.9-2.3 (m, 3H), 2.4 (m, 1H), 2.88(m, 1H), 3.18 (m, 1H), 3.56 (m, 1H), 3.70 (m, 1H), 6.94 (m, 2H), 7.10 (m, 2H).

EXAMPLE 12: 2β-(1-Propanoyl)-3β-(3,4-dichlorophenyl)nortropane  
(Compound **8** (R=3,4-Cl<sub>2</sub>), FIG. 3)

2β-(1-Propanoyl)-3β-(3,4-dichlorophenyl)tropane **7** (107 mg, 0.32 mmol) was combined with 1-chloroethyl chloroformate (2 mL) and the solution was heated to reflux for 5h. The excess chloroformate was removed in vacuo and the residue was refluxed in methanol for 45 min. The methanol was removed in vacuo and the residue was dissolved in CH<sub>2</sub>Cl<sub>2</sub> and shaken with NaHCO<sub>3</sub>/Na<sub>2</sub>CO<sub>3</sub> (pH=9). The aqueous layer was extracted CH<sub>2</sub>Cl<sub>2</sub> (4 x 10 mL) and the combined organic extracts were dried (Na<sub>2</sub>SO<sub>4</sub>), filtered and concentrated to yield 127 mg. This residue was chromatographed (1 x 100 mL 5% Et<sub>3</sub>N/EtOAc; 3 x 100 mL 10% Et<sub>3</sub>N/EtOAc). Like fractions were combined to yield **8** (30 mg, 29%).

<sup>1</sup>H-NMR (CDCl<sub>3</sub>) δ 0.76 (t, 3H), 1.4-2.5 (m, 9H), 2.92 (m, 1H), 3.09-3.2 (m, 1H), 3.6 (m, 1H), 3.72 (m, 1H), 7.0 (m, 1H), 7.25 (d, 1H), 7.32 (d, 1H).

EXAMPLE 13: N-[2-(3'-N'-Propyl-(1''R)-3''β-(4-fluorophenyl)tropane-2''β-(1-propanoyl))((2-((triphenylmethyl) thio)ethyl)amino)acetyl]-S-(triphenyl)-2-aminoethanethiol (Compound **9** (R=4-F), FIG. 3) (O-1507)

5        2β-(1-Propanoyl)-3β-(4-fluorophenyl)nortropane **8** (27 mg) was combined with MAMA'-Cl (86 mg), KI (34 mg, 2.0 eq.), and NaHCO<sub>3</sub> (43 mg, 5 eq.) in anhydrous MeCN (4 mL) and brought to reflux for 4h. The solvent was removed under vacuum and the residue was partitioned between CHCl<sub>3</sub> and saturated aqueous NaHCO<sub>3</sub>. The aqueous layer was extracted CHCl<sub>3</sub> (2 x 5 mL) and the combined organic extracts  
10        were dried (Na<sub>2</sub>SO<sub>4</sub>), filtered and concentrated to yield a brown foam. The foam was applied to a chromatography column (10 g silica; 40% EtOAc in hexanes/1% TEA). Fractions containing the product were combined and concentrated to yield **9** as a light foam (47 mg, 46%).

15        R<sub>f</sub> 0.09 (60% EtOAc/hexanes, 1% Et<sub>3</sub>N). Elemental analysis: calculated C, 72.15, H, 6.34, N, 3.96; found C, 71.99, H, 6.41, N, 3.92. <sup>1</sup>H-NMR (CDCl<sub>3</sub>) δ 0.77 (t, 3H), 1.2-3.1 (m, 29H), 3.3-3.5 (m, 2H), 6.9-7.0 (m, 2H), 7.1-7.6 (m, 32H).

EXAMPLE 14: N-[2-(3'-N'-Propyl-(1''R)-3''β-(3,4-dichlorophenyl)tropane-2''β-(1-propanoyl))((2-((triphenylmethyl) thio)ethyl)amino)acetyl]-S-(triphenyl)-2-aminoethanethiol (Compound **9** (R=3,4-Cl<sub>2</sub>), FIG. 3)

20        2β-(1-Propanoyl)-3β-(3,4-dichlorophenyl)nortropane **8** (30 mg, 0.096 mmol) was combined with MAMA'-Cl (87 mg, 0.115 mmol, 1.2 eq.), KI (32 mg, 0.19 mmol, 2.0

eq.), and NaHCO<sub>3</sub> (40 mg, 0.48 mmol, 5 eq.) in anhydrous MeCN (4 mL) and brought to reflux for 4h then cooled to room temperature and allowed to stir overnight. The solvent was removed under vacuum and the residue was partitioned between CH<sub>2</sub>Cl<sub>2</sub> (15 mL) and saturated aqueous NaHCO<sub>3</sub> (15 mL). The aqueous layer was extracted with CH<sub>2</sub>Cl<sub>2</sub> (3 x 10 mL) and the combined organic extracts were dried (Na<sub>2</sub>SO<sub>4</sub>), filtered and concentrated to yield a yellow oil (115 mg). The oil was applied to a chromatography column (10 g SiO<sub>2</sub>; 30% EtOAc in hexanes/1% Et<sub>3</sub>N). Fractions containing the product were combined and concentrated to yield **9** as a light foam (41 mg, 41%).

R<sub>f</sub> 0.14 (60% EtOAc/hexanes, 1% Et<sub>3</sub>N). <sup>1</sup>H-NMR (CDCl<sub>3</sub>) δ 0.81 (t, 3H), 1.2-3.1 (m, 29H), 3.34 (m, 1H), 3.52 (m, 1H), 7.0-7.6 (m, 33H).

EXAMPLE 15: N-[(2-((3'-N'-Propyl-(1''R)-3''β-(4-fluorophenyl)tropane-2''β-1-propanoyl)(2-mercaptoethyl)amino)acetyl)-2-aminoethane-thiolato]rhenium (V) oxide (Compound **10** (R=4-F), FIG. 3) (O-1508R)

N-[2-(3'-N'-Propyl-(1''R)-3''β-(4-fluorophenyl)tropane-2''β-(1-propanoyl))((2-((triphenylmethyl) thio)ethyl)amino)acetyl]-S-(triphenyl)-2-aminoethanethiol (22 mg, 0.023 mmol) was dissolved in boiling EtOH (abs. 4 mL) and SnCl<sub>2</sub> (8.5 mg, in 0.5 mL of 0.05M HCl). The reaction was maintained at reflux for a further 6h and silica was added and the solvents removed by evaporation. The silica adsorbed product was applied to a silica column (3g eluent: 30% EtOAc in hexanes with 5% Et<sub>3</sub>N). The

compound was obtained as a foam (6.7 mg, 44%).

R<sub>f</sub> 0.07 (60% EtOAc in hexanes + NH<sub>4</sub>OH (0.5%)) Accurate Mass calc for

C<sub>25</sub>H<sub>35</sub>FN<sub>3</sub>O<sub>3</sub>ReS<sub>2</sub> : 695.172; found 695.162. <sup>1</sup>H-NMR (CDCl<sub>3</sub>) δ 0.7-0.9 (2t, 2H),

5 1.4-4.1 (m, 26H), 4.5-4.6 (m, 1H), 4.73 (d, J=16.5 Hz, 0.5H) 4.87 (d, J=16.5 Hz, 0.5H),  
6.93 (m, 2H), 7.14 (m, 2H).

EXAMPLE 16: 2β-(Carboxylic acid)-3α-(4-fluorophenyl)tropane

(Compound **13** (R=4-F), FIG. 4)

10 A solution of 2β-methoxycarbonyl-3α-(4-fluorophenyl)-tropane **12** (1.0 g, 3.6  
mmol) was refluxed for 24h in 80 mL dioxane water (1:1). The solvent was removed in  
vacuo and the brown solid was purified by column chromatography (eluent 30%  
MeOH/CHCl<sub>3</sub>). The product (890 mg, 94%) was obtained as a white foam.

15 R<sub>f</sub> 0.43 (30% MeOH/CHCl<sub>3</sub>); NMR <sup>1</sup>H-NMR (CDCl<sub>3</sub>) δ 1.48-1.62 (m, 1H), 1.75-2.1 (m,  
3H), 2.36-2.46 (m, 1H), 2.60 (s, 3H), 2.7-2.82 (m, 1H), 3.22 (brs, 1H), 3.5-3.62 (m, 2H),  
3.76-3.84 (m, 1H), 6.9-7.1 (m, 2H), 7.4-7.5 (m, 2H).

EXAMPLE 17: 2β-(Carboxylic acid)-3α-(3,4-dichlorophenyl)tropane

20 (Compound **13** (R=3,4-Cl<sub>2</sub>), FIG. 4)

A solution of 2β-methoxycarbonyl-3α-(3,4-dichlorophenyl)tropane **12** (750 mg,  
2.29 mmol) and LiOH (335 mg, 8.0 mmol) was brought to reflux for 4h in water (10  
mL) and THF:MeOH (33 mL; 1:1). The reaction was neutralized by dropwise addition

of conc. HCl. The solvent was removed in vacuo and the product purified by column chromatography (eluent 15% MeOH/CHCl<sub>3</sub>). The product **13** (521 mg, 72 %) was obtained as a solid.

5 R<sub>f</sub> 0.15 (30% MeOH/CHCl<sub>3</sub>); <sup>1</sup>H-NMR (CD<sub>3</sub>OD) δ 1.59 (m, 1H), 1.8-1.9 (m, 1H), 2.1-2.2 (m, 2H), 2.6-2.7 (m, 2H), 2.76 (s, 3H), 3.25 (brs, 1H), 3.35 (brs, 1H), 3.85 (m, 1H), 3.93 (m, 1H), 7.5 (d, 1H), 7.53 (dd, 1H), 7.8 (d, 1H).

10 EXAMPLE 18: 2β-Methoxymethylcarbamoyl-3α-(4-fluorophenyl)tropane  
(Compound **14** (R=4-F), FIG. 4) (O-1403)

To a stirred suspension of Compound **13** (930 mg, 3.6 mmol) in anhydrous CH<sub>2</sub>Cl<sub>2</sub> (80 mL) containing DMF (50 μL) was added oxalyl chloride (1 mL, 11.4 mmol) dropwise resulting in copious bubbling and dissolution of the suspension. The reaction was allowed to stir for 45 min during which time the solution became yellow.  
15 It was then reduced in vacuo and pumped at high vacuum overnight, care being taken to bleed nitrogen into the evacuated flask when transferring from the rotary to the pump.

To the acid chloride dissolved in CH<sub>2</sub>Cl<sub>2</sub> (70 mL) was added (MeO)MeNH•HCl (382 mg, 3.9 mmol) followed immediately by pyridine (1 mL). The reaction was  
20 allowed to stir for 1h and then partitioned between CHCl<sub>3</sub> (20 mL) and 2M Na<sub>2</sub>CO<sub>3</sub> (20 mL). The aqueous layer was extracted with CHCl<sub>3</sub> (2 x 10 mL) and the combined organic extracts were dried over Na<sub>2</sub>SO<sub>4</sub>, filtered and reduced in vacuo to yield a yellow oil. The oil was dissolved in toluene and concentrated to yield a yellow solid

(653 mg). The crude product was dissolved in a minimum volume of  $\text{CHCl}_3$ , and applied to a chromatography column (28 g  $\text{SiO}_2$ ; eluent 25% hexanes in EtOAc, 5%  $\text{Et}_3\text{N}$ ; followed by 25% MeOH in  $\text{CHCl}_3$ ). Product containing fractions were combined and concentrated to yield the amide (540 mg; 50%).

5

$R_f$  0.25 (25% hexanes/EtOAc, 5%  $\text{Et}_3\text{N}$ ); mp. 139.8-141.7 °C;  $^1\text{H-NMR}$  ( $\text{CDCl}_3$ )  $\delta$  1.24 (dd, 1H), 1.4-1.8 (m, 3H), 2.1-2.3 (m, 2H), 2.23 (s, 3H), 2.4-2.6 (m, 1H), 2.7 (brd, 1H), 3.05 (s, 3H), 3.05-3.1 (m, 1H), 3.25-3.5 (m, 2H), 3.41 (s, 3H), 6.86-6.96 (m, 2H), 7.13-7.22 (m, 2H); IR (KBr) 2900, 1656, 1500  $\text{cm}^{-1}$ . Elemental analysis: calculated C, 66.65, H, 7.57, N, 9.14; found C, 66.37, H, 7.59, N, 9.0.

10

EXAMPLE 19: 2 $\beta$ -Methoxymethylcarbamoyl-3 $\alpha$ -(3,4-dichlorophenyl)tropane  
(Compound **14** (R=3,4- $\text{Cl}_2$ ), FIG. 4)

To a stirred suspension of the acid **13** (210 mg, 0.67 mmol) in anhydrous  $\text{CH}_2\text{Cl}_2$  (10 mL) containing DMF (30  $\mu\text{L}$ ) was added oxalyl chloride (0.3 mL, 2.0 mmol) dropwise. The reaction was allowed to stir for 1h and then reduced in vacuo and pumped at high vacuum overnight, care being taken to bleed nitrogen into the evacuated flask when transferring from the rotary to the pump.

15

To the acid chloride in  $\text{CH}_2\text{Cl}_2$  (10 mL) was added (MeO)MeNH. HCl (72 mg, 0.74 mmol) followed immediately by pyridine (0.3 mL). The reaction was allowed to stir for 1.5h and was partitioned between  $\text{CH}_2\text{Cl}_2$  (10 mL) and 1M  $\text{Na}_2\text{CO}_3$  solution (5 mL). The aqueous layer was extracted with  $\text{CH}_2\text{Cl}_2$  (10 mL) and the combined organic extracts were dried over  $\text{Na}_2\text{SO}_4$ , filtered and reduced in vacuo to yield a

20

yellow solid. The solid was purified by column chromatography (14 g SiO<sub>2</sub>, eluent 25% hexanes/EtOAc, 5% Et<sub>3</sub>N). Product containing fractions were combined and concentrated to yield the amide (115 mg; 48%).

5 R<sub>f</sub> 0.14 (40% hexanes/EtOAc, 5% Et<sub>3</sub>N); <sup>1</sup>H-NMR (CDCl<sub>3</sub>) δ 1.17 (ddd, 1H), 1.48 (ddd, 1H), 1.63 (ddd, 1H), 2.1-2.34 (m, 2H), 2.21 (s, 3H), 2.42-2.54 (m, 1H), 2.65 (brd, 1H), 3.06 (s, 3H), 3.08 (brs, 1H), 3.22-3.32 (m, 1H), 3.34-3.46 (m, 1H), 3.48 (s, 3H), 7.05 (dd, 1H), 7.25 (d, 1H), 7.27 (d, 1H).

10 EXAMPLE 20: 2β-(1-Propanoyl)-3α-(4-fluorophenyl)-tropane

(Compound 15 (R=4-F), FIG. 4) (O-1369)

A 250 mL round bottom flask containing the 2β-methoxymethylcarbamoyl-3α-(4-fluorophenyl)tropane 14 (471 mg) was flushed with nitrogen and charged with anhydrous THF (70 mL). At room temperature, EtMgBr/Et<sub>2</sub>O (3.0 mL; 3.0M) was added dropwise over 3 min. The reaction was stirred at room temperature for 30 min and was then heated to 65°C for 1h at which point no starting material was observed by TLC (TLC sample was prepared by adding an aliquot of the reaction to ethereal HCl, and basifying with 2M Na<sub>2</sub>CO<sub>3</sub>; R<sub>f</sub> (product) 0.42; R<sub>f</sub> (starting material) 0.13 (20% EtOAc/hexanes, 5% Et<sub>3</sub>N). The reaction was cooled in an ice bath and  
20 quenched by slow addition of ethereal HCl. The cloudy solution was basified with 2M Na<sub>2</sub>CO<sub>3</sub> and diluted with ether (25 mL). The layers were separated and the aqueous layer was extracted with ether (1 x 10 mL) and CHCl<sub>3</sub> (2 x 20 mL). The combined organic extracts were dried (Na<sub>2</sub>SO<sub>4</sub>), filtered and reduced in vacuo to yield the crude

residue (484 mg). This residue was then chromatographed (25 g SiO<sub>2</sub>; eluent 25% EtOAc/hexanes, 5% Et<sub>3</sub>N). Fractions containing the product were combined and concentrated to yield **15** (300 mg, 70%);

5 Mp. 60.5-61.3 °C; R<sub>f</sub> 0.49 (33% EtOAc/hexanes; 5% Et<sub>3</sub>N); <sup>1</sup>H-NMR (CDCl<sub>3</sub>) δ 0.86 (t, 3H), 1.27 (ddd, 1H), 1.4-1.6 (m, 2H), 2.0-2.5 (m, 6H), 2.23 (s, 3H), 3.12 (brd, 1H), 3.2-3.3 (m, 2H), 6.85-7.0 (m, 2H), 7.05-7.15 (m, 2H); IR (KBr) 2900, 1740, 1500 cm<sup>-1</sup>; Elemental analysis: calculated C, 74.15, H, 8.05, N, 5.09; found C, 74.00, H, 8.13, N, 4.98

10  
EXAMPLE 21: 2β-(1-Propanoyl)-3α-(3,4-dichlorophenyl)tropane  
(Compound **15** (R=3,4-Cl<sub>2</sub>), FIG. 4)

2β-Methoxymethylcarbamoyl-3α-(3,4-dichlorophenyl)tropane, **14** (105 mg, 0.29 mmol) was flushed with nitrogen and charged with anhydrous THF (15 mL). At room temperature, EtMgBr/Et<sub>2</sub>O (0.8 mL; 3.0M) was added dropwise over 3 min. The  
15 reaction was stirred at room temperature for 1h and was then heated to 55°C for 30 min at which point no starting material was observed by TLC. The reaction was cooled in an ice bath and quenched by slow addition of ethereal HCl. The cloudy solution was basified with 2M Na<sub>2</sub>CO<sub>3</sub> and diluted with ether (15 mL) and water (15  
20 mL). The layers were separated and the aqueous layer was extracted with CHCl<sub>3</sub> (2 x 15 mL). The combined organic extracts were dried (Na<sub>2</sub>SO<sub>4</sub>), filtered and reduced in vacuo to yield a residue (95 mg) which was chromatographed (5 g SiO<sub>2</sub>, eluent 25% EtOAc in hexanes, 5% Et<sub>3</sub>N). Fractions containing the product were combined and



concentrated to yield **15** (80 mg, 80%).

R<sub>f</sub> 0.28 (30% EtOAc/hexanes; 5% Et<sub>3</sub>N); <sup>1</sup>H-NMR (CDCl<sub>3</sub>) 0.93 (t, J=7.4Hz, 3H),  
1.27 (ddd, 1H), 1.42-1.62 (m, 2H), 2.06-2.30 (m, 6H), 2.21 (s, 3H), 3.32-2.52 (m, 3H),  
5 3.14 (brd 1H), 3.2-3.36 (m, 2H), 7.10 (dd, 1H), 7.24 (d, 1H), 7.29 (d, 1H).

EXAMPLE 21a: 2β-(1-Propanoyl)-3α-(3,4-dichlorophenyl)tropane  
(Compound **15** (R-3,4-Cl<sub>2</sub>), FIG. 4)

To commercially available ethylmagnesium bromide (1M in THF, 12.6 mL, 12.6  
10 mmol) in a flask equipped with an addition funnel under nitrogen was added  
triethylamine (5.0 g, 50.4 mmol). To the resulting mixture was added drop-wise a  
solution of compound **12** (R=Cl<sub>2</sub>, 750 mg, 2.29 mmol) in benzene (10 mL) at 5-10°C  
over a period of 1 hour. The reaction mixture was then stirred at 5-10°C for 5 hours  
and then treated with 4 M HCl (2.9 mL, 11.6 mmol). The organic layer was washed  
15 with water (1 x 50 mL), 5% NaHCO<sub>3</sub> (aq) (1 x 50 mL) and water (2 x 50 mL). The  
organic phase was then dried (K<sub>2</sub>CO<sub>3</sub>), filtered and the concentrated. The residue was  
chromatographed (SiO<sub>2</sub>. 25% EtOAc in hexanes with 5% Et<sub>3</sub>N) and gave 670 mg (85%)  
of compound **15** with the same physical and spectral characteristics as previously  
reported (Example 21).

20  
EXAMPLE 22: 2β-(1-Propanoyl)-3α-(4-fluorophenyl)nortropane  
(Compound **16** (R=4-F), FIG. 4) (O-1370)

2β-(1-Propanoyl)-3α-(4-fluorophenyl)tropane **15** (O-1369) (556 mg, 2 mmol) and  
ACE-Cl (7 mL) were combined and brought to reflux for 4h. All volatiles were removed

by evaporation and methanol ( 100 mL) was added to the residue. The resulting mixture was brought to reflux for 90 min. Volatiles were removed and the residue was taken up in CHCl<sub>3</sub> and washed with aq. 2M Na<sub>2</sub>CO<sub>3</sub>. The aqueous mixture was extracted with CHCl<sub>3</sub> (2 x 10 mL) and organic fractions combined, dried (Na<sub>2</sub>SO<sub>4</sub>),  
5 filtered and reduced. The dark brown oil (615 mg) was chromatographed (SiO<sub>2</sub>, 20 g; 0 -10% Et<sub>3</sub>N in EtOAc) and gave 390 mg (74%) of a yellow oil.

R<sub>f</sub> 0.25 (5% Et<sub>3</sub>N in EtOAc); <sup>1</sup>H-NMR (CDCl<sub>3</sub>) δ 0.86 (t, 3H), 1.27 (ddd, 1H), 1.50-1.72 (m, 2H), 1.8-2.1 (m, 3H), 2.2-2.4 (m, 2H), 2.56 (dd, J=10.7, 1Hz, 1H), 3.07 (ddd, J=11.3, 10.9, 7.1Hz, 1H), 3.43 (brd 1H), 3.62 (brt, 1H), 6.89-6.99 (m, 2H), 7.09-7.16 (m, 2H). IR (KBr) 2900, 1711, 1500 cm<sup>-1</sup>; Elemental analysis: calculated (0.2 H<sub>2</sub>O) C, 72.52, H, 7.77, N, 5.25; found C, 72.65, H, 7.81, N, 5.27

EXAMPLE 23: 2β-(1-Propanoyl)-3α-(3,4-dichlorophenyl)nortropane  
(Compound **16** (R=3,4-Cl<sub>2</sub>), FIG. 4)

2β-(1-Propanoyl)-3-(3,4-dichlorophenyl)tropane, **15** (80 mg, 2.45 mmol) was combined with 1-chloroethyl chloroformate (3 mL) and the solution was heated to reflux for 5h. The excess chloroformate was removed in vacuo and the residue was refluxed in methanol for 1h. The methanol was removed in vacuo and the residue  
20 was dissolved in CHCl<sub>3</sub> and washed with 2M Na<sub>2</sub>CO<sub>3</sub>. The aqueous layer was extracted with CHCl<sub>3</sub> (2 x 5 mL) and the combined organic extracts were dried (Na<sub>2</sub>SO<sub>4</sub>), filtered and concentrated to yield pure compound (77 mg; 100%).

R<sub>f</sub> 0.3 (5% Et<sub>3</sub>N/EtOAc); <sup>1</sup>H-NMR (CDCl<sub>3</sub>) δ 0.91 (t, 3H), 1.25 (ddd, 1H, 1.52-1.74 (m, 2H), 1.8-2.56 (m, 7H), 3.06-3.2 (m, 1H), 3.45 (d, 1H), 3.62 (brt, 1H), 7.01 (dd, 1H), 7.25 (d, 1H), 7.31 (d, 1H).

5. EXAMPLE 24: N-[2-(3'-N'-Propyl-(1''R)-3''α-(4-fluorophenyl)tropane-2''β-(1-propanoyl))((2-((triphenylmethyl) thio)ethyl)amino)acetyl]-S-(triphenyl)-2-aminoethanethiol (compound **17** (R=4-F), FIG. 4) (O-1506)

2β-(1-Propanoyl)-3α-(4-fluorophenyl)nortropane **16** (24 mg, 0.09 mmol),  
10 MAMA'-Cl (147 mg, 0.19 mmol), KI (31 mg, 19 mmol) were all dissolved in CH<sub>3</sub>CN (3 mL) and brought to reflux for 3h. Solvent was removed in vacuo and the residue partitioned between satd. aq NaHCO<sub>3</sub> and CHCl<sub>3</sub>. The aqueous layer was further extracted with CHCl<sub>3</sub>, all organic fractions were combined and dried (Na<sub>2</sub>SO<sub>4</sub>), filtered and concentrated. Column chromatography (20% EtOAc, 79% Hexane, 1%  
15 Et<sub>3</sub>N) gave pure product as a golden foam (11.5 mg, 13%).

R<sub>f</sub> 0.15 (50% EtOAc in hexanes + 5% Et<sub>3</sub>N); Elemental analysis: calculated (0.1H<sub>2</sub>O) C, 75.79, H, 6.87, N, 4.21; found C, 75.35, H, 6.81, N, 4.13. <sup>1</sup>H-NMR (CDCl<sub>3</sub>) δ 0.85 (t, 3H), 1.19 (ddd, 1H), 1.3-1.5 (m, 6H), 1.8-2.6 (m, 14H), 2.85 (brs, 2H), 3.0 (m, 2H),  
20 3.08-3.30 (m, 3H), 6.88-6.96 (m, 2H), 7.06-7.42 (m, 32H).

EXAMPLE 25: N-[2-(3'-N'-Propyl-(1''R)-3'' $\alpha$ -(3,4-dichlorophenyl)tropane-2'' $\beta$ -(1'''-propanoyl))((2-((triphenylmethyl) thio)ethyl)amino)acetyl]-S-(triphenyl)-2-aminoethanethiol (Compound **17** (R=3,4-Cl<sub>2</sub>), FIG.4) (O-1546)

5           2 $\beta$ -(1-Propanoyl)-3 $\alpha$ -(3,4-dichlorophenyl)nortropane **16** (75 mg, 0.24 mmol) was combined with N-(((2-(2-(triphenylmethyl) thio)ethyl)(N'-3'-chloropropyl)amino)-acetyl)-S-(triphenylmethyl)-2-aminoethanethiol (MAMA'-Cl) (218 mg, 0.29 mmol), KI (80 mg, 0.48 mmol), and NaHCO<sub>3</sub> (101 mg, 1.2 mmol) in anhydrous MeCN (20 mL) and brought to reflux for 4h then cooled to room temperature. The solvent was removed under vacuum and the residue was partitioned between CH<sub>2</sub>Cl<sub>2</sub> (20 mL) and saturated aqueous NaHCO<sub>3</sub> (15 mL). The aqueous layer was extracted with CH<sub>2</sub>Cl<sub>2</sub> (1 x 10 mL) and the combined organic extracts were dried (Na<sub>2</sub>SO<sub>4</sub>), filtered and concentrated to yield a brown oil. The oil was applied to a chromatography column (30 g SiO<sub>2</sub>; eluent: 25% EtOAc/hexanes/1% Et<sub>3</sub>N). Fractions containing the product were combined and concentrated to yield **17** (51 mg, 17%).

R<sub>f</sub> 0.3 (60% EtOAc in hexanes, 1% Et<sub>3</sub>N); Elemental analysis: calculated (1.33 H<sub>2</sub>O) C, 71.71, H, 6.46, N, 3.98; found C, 71.85, H, 6.52, N, 3.91. <sup>1</sup>H-NMR (CDCl<sub>3</sub>)  $\delta$  0.89 (t, 3H), 1.0-1.7 (m, 8H), 1.8-2.5 (m, 14H), 2.6-3.4 (m, 6H), 6.9-7.6 (m, 33H).

EXAMPLE 26: N-[(2-((3'-N'-Propyl-(1''R)-3'' $\alpha$ -(4-fluorophenyl)tropane-2'' $\beta$ -1'''-propanoyl))(2-mercaptoethyl)amino)acetyl)-2-aminoethanethiolato]rhenium (V) oxide (Compound **18** (R=4-F), FIG. 4) (O-1505)

5 A solution of N-[2-(3'-N'-Propyl-(1''R)-3'' $\alpha$ -(4-fluorophenyl)tropane-2'' $\beta$ -(1'''-propanoyl))((2-((triphenylmethyl) thio)ethyl)amino)acetyl)-S-(triphenyl)-2-aminoethanethiol, **17** (22 mg) in EtOH (4 mL) was heated to reflux. A solution of SnCl<sub>2</sub> (7.8 mg, 0.04 mmol) in 0.005 M HCl (0.5 mL) was added quickly followed immediately by NaReO<sub>4</sub> (12.4 mg, 0.04 mmol) in 0.005 M HCl (0.5 mL). The cloudy  
10 solution was refluxed for 6h and was then loaded onto 0.5 g silica and pumped overnight. The silica-adsorbed material was applied to a chromatography column (3 g SiO<sub>2</sub>; eluent 30% EtOAc/hexanes/5% TEA). The purple brown solid obtained was triturated with pentane and dried at high vacuum overnight to yield **18** as a foam (9.9 mg; 71%).

15 Accurate Mass calc 695.161 (found, 695.172). R<sub>f</sub> 0.30 (75% EtOAc in hexane + 0.5% NH<sub>4</sub>OH); <sup>1</sup>H-NMR (CDCl<sub>3</sub>)  $\delta$  0.75-0.95 (2t, 3H), 1.0-2.0 (m, 8H), 2.0-2.5 (m, 6H), 2.8-3.0 (m, 1H), 3.0-3.5 (m, 7H), 3.6-3.8 (m, 1H), 3.9-4.2 (m, 3H), 4.5-4.65 (m, 1H), 4.73, 5.12 (2d, J=16.7Hz), 6.9-7.0 (m, 2H), 7.08-7.15 (m, 2H).

EXAMPLE 27: N-[(2-((3'-N'-Propyl-(1''R)-3'' $\alpha$ -(3,4-dichlorophenyl)tropane-2'' $\beta$ -1'''-propanoyl)(2-mercaptoethyl)amino)acetyl)-2-aminoethane-thiolato]rhenium (V) oxide (Compound **18** (R=3,4-Cl<sub>2</sub>), FIG. 4)

A solution of N-[2-(3'-N'-Propyl-(1''R)-3'' $\alpha$ -(3,4-dichlorophenyl)tropane-2'' $\beta$ -(1-  
5 propanoyl))(2-((triphenylmethyl) thio)ethyl)amino)acetyl]-S-(triphenyl)-2-aminoethanethiol, **17**, (24 mg, 0.024 mmol) in EtOH (5 mL) was heated to reflux. A solution of SnCl<sub>2</sub> (9 mg, 0.05 mmol) in 0.005 M HCl (0.5 mL) was added quickly followed immediately by NaReO<sub>4</sub> (14.5 mg, 0.05 mmol) in 0.005 M HCl (0.5 mL). The solution was refluxed for 4h and was then loaded onto 0.5 g silica and pumped at  
10 high vacuum overnight. The silica-adsorbed material was applied to a chromatography column (4 g SiO<sub>2</sub>; eluent 30% EtOAc/hexanes/5% Et<sub>3</sub>N). The solid obtained was concentrated to yield **18** (4.6 mg; 27%).

<sup>1</sup>H-NMR (CDCl<sub>3</sub>)  $\delta$  0.8-1.0 (2t, 3H), 1.1-2.5 (m, 14H), 2.8-3.0 (m, 1H), 3.0-3.5 (m, 7H),  
15 3.6-3.8 (m, 1H), 3.9-4.2 (m, 3H), 4.4-4.65 (m, 1H), 4.70, 5.06 (2d, 2xJ=16.7Hz, 1H), 7.0 (dd, 1H), 7.3 (d, 1H), 7.34 (d, 1H).

EXAMPLE 28: 2 $\beta$ -(Methoxymethylcarbamoyl-3 $\alpha$ -(4-fluorophenyl)nortropane  
(compound **20** (R=4-F), FIG. 5)

20 2 $\beta$ -(1-Propanoyl)-3 $\alpha$ -(4-fluorophenyl)tropane **14** (112 mg, 0.37 mmol) was combined with 1-chloroethyl chloroformate (2.2 mL) and the solution was heated to reflux for 5h. The excess chloroformate was removed in vacuo and the residue was refluxed in methanol for 45 min. The MeOH was removed in vacuo and the residue

was dissolved in  $\text{CHCl}_3$  and  $\text{NaHCO}_3/\text{Na}_2\text{CO}_3$  (pH=9). The aqueous layer was extracted  $\text{CHCl}_3$  (3 x 10 mL) and the combined organic extracts were dried ( $\text{Na}_2\text{SO}_4$ ), filtered and concentrated to yield 104 mg. This residue was chromatographed (eluent: 10-20%  $\text{Et}_3\text{N}$  in  $\text{EtOAc}$ ). Like fractions were combined to yield **20** (65 mg, 60%).

5

$R_f$  0.13 (10%  $\text{Et}_3\text{N}$  in  $\text{EtOAc}$ );  $^1\text{H-NMR}$  ( $\text{CDCl}_3$ )  $\delta$  1.30 (ddd, 1H), 1.5-1.75 (m, 2H), 1.85-2.15 (m, 2H), 2.2-2.35 (m, 1H), 2.7-2.9 (m, 1H), 3.05 (s, 3H), 3.1-3.22 (m, 1H), 3.38 (s, 3H), 3.4-3.5 (m, 1H), 3.6-3.7 (m, 1H), 6.9-7.0 (m, 2H), 7.13-7.23 (m, 2H).

10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65  
66  
67  
68  
69  
70  
71  
72  
73  
74  
75  
76  
77  
78  
79  
80  
81  
82  
83  
84  
85  
86  
87  
88  
89  
90  
91  
92  
93  
94  
95  
96  
97  
98  
99  
100  
101  
102  
103  
104  
105  
106  
107  
108  
109  
110  
111  
112  
113  
114  
115  
116  
117  
118  
119  
120  
121  
122  
123  
124  
125  
126  
127  
128  
129  
130  
131  
132  
133  
134  
135  
136  
137  
138  
139  
140  
141  
142  
143  
144  
145  
146  
147  
148  
149  
150  
151  
152  
153  
154  
155  
156  
157  
158  
159  
160  
161  
162  
163  
164  
165  
166  
167  
168  
169  
170  
171  
172  
173  
174  
175  
176  
177  
178  
179  
180  
181  
182  
183  
184  
185  
186  
187  
188  
189  
190  
191  
192  
193  
194  
195  
196  
197  
198  
199  
200  
201  
202  
203  
204  
205  
206  
207  
208  
209  
210  
211  
212  
213  
214  
215  
216  
217  
218  
219  
220  
221  
222  
223  
224  
225  
226  
227  
228  
229  
230  
231  
232  
233  
234  
235  
236  
237  
238  
239  
240  
241  
242  
243  
244  
245  
246  
247  
248  
249  
250  
251  
252  
253  
254  
255  
256  
257  
258  
259  
260  
261  
262  
263  
264  
265  
266  
267  
268  
269  
270  
271  
272  
273  
274  
275  
276  
277  
278  
279  
280  
281  
282  
283  
284  
285  
286  
287  
288  
289  
290  
291  
292  
293  
294  
295  
296  
297  
298  
299  
300  
301  
302  
303  
304  
305  
306  
307  
308  
309  
310  
311  
312  
313  
314  
315  
316  
317  
318  
319  
320  
321  
322  
323  
324  
325  
326  
327  
328  
329  
330  
331  
332  
333  
334  
335  
336  
337  
338  
339  
340  
341  
342  
343  
344  
345  
346  
347  
348  
349  
350  
351  
352  
353  
354  
355  
356  
357  
358  
359  
360  
361  
362  
363  
364  
365  
366  
367  
368  
369  
370  
371  
372  
373  
374  
375  
376  
377  
378  
379  
380  
381  
382  
383  
384  
385  
386  
387  
388  
389  
390  
391  
392  
393  
394  
395  
396  
397  
398  
399  
400  
401  
402  
403  
404  
405  
406  
407  
408  
409  
410  
411  
412  
413  
414  
415  
416  
417  
418  
419  
420  
421  
422  
423  
424  
425  
426  
427  
428  
429  
430  
431  
432  
433  
434  
435  
436  
437  
438  
439  
440  
441  
442  
443  
444  
445  
446  
447  
448  
449  
450  
451  
452  
453  
454  
455  
456  
457  
458  
459  
460  
461  
462  
463  
464  
465  
466  
467  
468  
469  
470  
471  
472  
473  
474  
475  
476  
477  
478  
479  
480  
481  
482  
483  
484  
485  
486  
487  
488  
489  
490  
491  
492  
493  
494  
495  
496  
497  
498  
499  
500  
501  
502  
503  
504  
505  
506  
507  
508  
509  
510  
511  
512  
513  
514  
515  
516  
517  
518  
519  
520  
521  
522  
523  
524  
525  
526  
527  
528  
529  
530  
531  
532  
533  
534  
535  
536  
537  
538  
539  
540  
541  
542  
543  
544  
545  
546  
547  
548  
549  
550  
551  
552  
553  
554  
555  
556  
557  
558  
559  
560  
561  
562  
563  
564  
565  
566  
567  
568  
569  
570  
571  
572  
573  
574  
575  
576  
577  
578  
579  
580  
581  
582  
583  
584  
585  
586  
587  
588  
589  
590  
591  
592  
593  
594  
595  
596  
597  
598  
599  
600  
601  
602  
603  
604  
605  
606  
607  
608  
609  
610  
611  
612  
613  
614  
615  
616  
617  
618  
619  
620  
621  
622  
623  
624  
625  
626  
627  
628  
629  
630  
631  
632  
633  
634  
635  
636  
637  
638  
639  
640  
641  
642  
643  
644  
645  
646  
647  
648  
649  
650  
651  
652  
653  
654  
655  
656  
657  
658  
659  
660  
661  
662  
663  
664  
665  
666  
667  
668  
669  
670  
671  
672  
673  
674  
675  
676  
677  
678  
679  
680  
681  
682  
683  
684  
685  
686  
687  
688  
689  
690  
691  
692  
693  
694  
695  
696  
697  
698  
699  
700  
701  
702  
703  
704  
705  
706  
707  
708  
709  
710  
711  
712  
713  
714  
715  
716  
717  
718  
719  
720  
721  
722  
723  
724  
725  
726  
727  
728  
729  
730  
731  
732  
733  
734  
735  
736  
737  
738  
739  
740  
741  
742  
743  
744  
745  
746  
747  
748  
749  
750  
751  
752  
753  
754  
755  
756  
757  
758  
759  
760  
761  
762  
763  
764  
765  
766  
767  
768  
769  
770  
771  
772  
773  
774  
775  
776  
777  
778  
779  
780  
781  
782  
783  
784  
785  
786  
787  
788  
789  
790  
791  
792  
793  
794  
795  
796  
797  
798  
799  
800  
801  
802  
803  
804  
805  
806  
807  
808  
809  
810  
811  
812  
813  
814  
815  
816  
817  
818  
819  
820  
821  
822  
823  
824  
825  
826  
827  
828  
829  
830  
831  
832  
833  
834  
835  
836  
837  
838  
839  
840  
841  
842  
843  
844  
845  
846  
847  
848  
849  
850  
851  
852  
853  
854  
855  
856  
857  
858  
859  
860  
861  
862  
863  
864  
865  
866  
867  
868  
869  
870  
871  
872  
873  
874  
875  
876  
877  
878  
879  
880  
881  
882  
883  
884  
885  
886  
887  
888  
889  
890  
891  
892  
893  
894  
895  
896  
897  
898  
899  
900  
901  
902  
903  
904  
905  
906  
907  
908  
909  
910  
911  
912  
913  
914  
915  
916  
917  
918  
919  
920  
921  
922  
923  
924  
925  
926  
927  
928  
929  
930  
931  
932  
933  
934  
935  
936  
937  
938  
939  
940  
941  
942  
943  
944  
945  
946  
947  
948  
949  
950  
951  
952  
953  
954  
955  
956  
957  
958  
959  
960  
961  
962  
963  
964  
965  
966  
967  
968  
969  
970  
971  
972  
973  
974  
975  
976  
977  
978  
979  
980  
981  
982  
983  
984  
985  
986  
987  
988  
989  
990  
991  
992  
993  
994  
995  
996  
997  
998  
999  
1000  
1001  
1002  
1003  
1004  
1005  
1006  
1007  
1008  
1009  
1010  
1011  
1012  
1013  
1014  
1015  
1016  
1017  
1018  
1019  
1020  
1021  
1022  
1023  
1024  
1025  
1026  
1027  
1028  
1029  
1030  
1031  
1032  
1033  
1034  
1035  
1036  
1037  
1038  
1039  
1040  
1041  
1042  
1043  
1044  
1045  
1046  
1047  
1048  
1049  
1050  
1051  
1052  
1053  
1054  
1055  
1056  
1057  
1058  
1059  
1060  
1061  
1062  
1063  
1064  
1065  
1066  
1067  
1068  
1069  
1070  
1071  
1072  
1073  
1074  
1075  
1076  
1077  
1078  
1079  
1080  
1081  
1082  
1083  
1084  
1085  
1086  
1087  
1088  
1089  
1090  
1091  
1092  
1093  
1094  
1095  
1096  
1097  
1098  
1099  
1100  
1101  
1102  
1103  
1104  
1105  
1106  
1107  
1108  
1109  
1110  
1111  
1112  
1113  
1114  
1115  
1116  
1117  
1118  
1119  
1120  
1121  
1122  
1123  
1124  
1125  
1126  
1127  
1128  
1129  
1130  
1131  
1132  
1133  
1134  
1135  
1136  
1137  
1138  
1139  
1140  
1141  
1142  
1143  
1144  
1145  
1146  
1147  
1148  
1149  
1150  
1151  
1152  
1153  
1154  
1155  
1156  
1157  
1158  
1159  
1160  
1161  
1162  
1163  
1164  
1165  
1166  
1167  
1168  
1169  
1170  
1171  
1172  
1173  
1174  
1175  
1176  
1177  
1178  
1179  
1180  
1181  
1182  
1183  
1184  
1185  
1186  
1187  
1188  
1189  
1190  
1191  
1192  
1193  
1194  
1195  
1196  
1197  
1198  
1199  
1200  
1201  
1202  
1203  
1204  
1205  
1206  
1207  
1208  
1209  
1210  
1211  
1212  
1213  
1214  
1215  
1216  
1217  
1218  
1219  
1220  
1221  
1222  
1223  
1224  
1225  
1226  
1227  
1228  
1229  
1230  
1231  
1232  
1233  
1234  
1235  
1236  
1237  
1238  
1239  
1240  
1241  
1242  
1243  
1244  
1245  
1246  
1247  
1248  
1249  
1250  
1251  
1252  
1253  
1254  
1255  
1256  
1257  
1258  
1259  
1260  
1261  
1262  
1263  
1264  
1265  
1266  
1267  
1268  
1269  
1270  
1271  
1272  
1273  
1274  
1275  
1276  
1277  
1278  
1279  
1280  
1281  
1282  
1283  
1284  
1285  
1286  
1287  
1288  
1289  
1290  
1291  
1292  
1293  
1294  
1295  
1296  
1297  
1298  
1299  
1300  
1301  
1302  
1303  
1304  
1305  
1306  
1307  
1308  
1309  
1310  
1311  
1312  
1313  
1314  
1315  
1316  
1317  
1318  
1319  
1320  
1321  
1322  
1323  
1324  
1325  
1326  
1327  
1328  
1329  
1330  
1331  
1332  
1333  
1334  
1335  
1336  
1337  
1338  
1339  
1340  
1341  
1342  
1343  
1344  
1345  
1346  
1347  
1348  
1349  
1350  
1351  
1352  
1353  
1354  
1355  
1356  
1357  
1358  
1359  
1360  
1361  
1362  
1363  
1364  
1365  
1366  
1367  
1368  
1369  
1370  
1371  
1372  
1373  
1374  
1375  
1376  
1377  
1378  
1379  
1380  
1381  
1382  
1383  
1384  
1385  
1386  
1387  
1388  
1389  
1390  
1391  
1392  
1393  
1394  
1395  
1396  
1397  
1398  
1399  
1400  
1401  
1402  
1403  
1404  
1405  
1406  
1407  
1408  
1409  
1410  
1411  
1412  
1413  
1414  
1415  
1416  
1417  
1418  
1419  
1420  
1421  
1422  
1423  
1424  
1425  
1426  
1427  
1428  
1429  
1430  
1431  
1432  
1433  
1434  
1435  
1436  
1437  
1438  
1439  
1440  
1441  
1442  
1443  
1444  
1445  
1446  
1447  
1448  
1449  
1450  
1451  
1452  
1453  
1454  
1455  
1456  
1457  
1458  
1459  
1460  
1461  
1462  
1463  
1464  
1465  
1466  
1467  
1468  
1469  
1470  
1471  
1472  
1473  
1474  
1475  
1476  
1477  
1478  
1479  
1480  
1481  
1482  
1483  
1484  
1485  
1486  
1487  
1488  
1489  
1490  
1491  
1492  
1493  
1494  
1495  
1496  
1497  
1498  
1499  
1500  
1501  
1502  
1503  
1504  
1505  
1506  
1507  
1508  
1509  
1510  
1511  
1512  
1513  
1514  
1515  
1516  
1517  
1518  
1519  
1520  
1521  
1522  
1523  
1524  
1525  
1526  
1527  
1528  
1529  
1530  
1531  
1532  
1533  
1534  
1535  
1536  
1537  
1538  
1539  
1540  
1541  
1542  
1543  
1544  
1545  
1546  
1547  
1548  
1549  
1550  
1551  
1552  
1553  
1554  
1555  
1556  
1557  
1558  
1559  
1560  
1561  
1562  
1563  
1564  
1565  
1566  
1567  
1568  
1569  
1570  
1571  
1572  
1573  
1574  
1575  
1576  
1577  
1578  
1579  
1580  
1581  
1582  
1583  
1584  
1585  
1586  
1587  
1588  
1589  
1590  
1591  
1592  
1593  
1594  
1595  
1596  
1597  
1598  
1599  
1600  
1601  
1602  
1603  
1604  
1605  
1606  
1607  
1608  
1609  
1610  
1611  
1612  
1613  
1614  
1615  
1616  
1617  
1618  
1619  
1620  
1621  
1622  
1623  
1624  
1625  
1626  
1627  
1628  
1629  
1630  
1631  
1632  
1633  
1634  
1635  
1636  
1637  
1638  
1639  
1640  
1641  
1642  
1643  
1644  
1645  
1646  
1647  
1648  
1649  
1650  
1651  
1652  
1653  
1654  
1655  
1656  
1657  
1658  
1659  
1660  
1661  
1662  
1663  
1664  
1665  
1666  
1667  
1668  
1669  
1670  
1671  
1672  
1673  
1674  
1675  
1676  
1677  
1678  
1679  
1680  
1681  
1682  
1683  
1684  
1685  
1686  
1687  
1688  
1689  
1690  
1691  
1692  
1693  
1694  
1695  
1696  
1697  
1698  
1699  
1700  
1701  
1702  
1703  
1704  
1705  
1706  
1707  
1708  
1709  
1710  
1711  
1712  
1713  
1714  
1715  
1716  
1717  
1718  
1719  
1720  
1721  
1722  
1723  
1724  
1725  
1726  
1727  
1728  
1729  
1730  
1731  
1732  
1733  
1734  
1735  
1736  
1737  
1738  
1739  
1740  
1741  
1742  
1743  
1744  
1745  
1746  
1747  
1748  
1749  
1750  
1751  
1752  
1753  
1754  
1755  
1756  
1757  
1758  
1759  
1760  
1761  
1762  
1763  
1764  
1765  
1766  
1767  
1768  
1769  
1770  
1771  
1772  
1773  
1774  
1775  
1776  
1777  
1778  
1779  
1780  
1781  
1782  
1783  
1784  
1785  
1786  
1787  
1788  
1789  
1790  
1791  
1792  
1793  
1794  
1795  
1796  
1797  
1798  
1799  
1800  
1801  
1802  
1803  
1804  
1805  
1806  
1807  
1808  
1809  
1810  
1811  
1812  
1813  
1814  
1815  
1816  
1817  
1818  
1819  
1820  
1821  
1822  
1823  
1824  
1825  
1826  
1827  
1828  
1829  
1830  
1831  
1832  
1833  
1834  
1835  
1836  
1837  
1838  
1839  
1840  
1841  
1842  
1843  
1844  
1845  
1846  
1847  
1848  
1849  
1850  
1851  
1852  
1853  
1854  
1855  
1856  
1857  
1858  
1859  
1860  
1861  
1862  
1863  
1864  
1865  
1866  
1867  
1868  
1869  
1870  
1871  
1872  
1873  
1874  
1875  
1876  
1877  
1878  
1879  
1880  
1881  
1882  
1883  
1884  
1885  
1886  
1887  
1888  
1889  
1890  
1891  
1892  
1893  
1894  
1895  
1896  
1897  
1898  
1899  
1900  
1901  
1902  
1903  
1904  
1905  
1906  
1907  
1908  
1909  
1910  
1911  
1912  
1913  
1914  
1915  
1916  
1917  
1918  
1919  
1920  
1921  
1922  
1923  
1924  
1925  
1926  
1927  
1928  
1929  
1930  
1931  
1932  
1933  
1934  
1935  
1936  
1937  
1938  
1939  
1940  
1941  
1942  
1943  
1944  
1945  
1946  
1947  
1948  
1949  
1950  
1951  
1952  
1953  
1954  
1955  
1956  
1957  
1958  
1959  
1960  
1961  
1962  
1963  
1964  
1965  
1966  
1967  
1968  
1969  
1970  
1971  
1972  
1973  
1974  
1975  
1976  
1977  
1978  
1979  
1980  
1981  
1982  
1983  
1984  
1985  
1986  
1987  
1988  
1989  
1990  
1991  
1992  
1993  
1994  
1995  
1996  
1997  
1998  
1999  
2000  
2001  
2002  
2003  
2004  
2005  
2006  
2007  
2008  
2009  
2010  
2011  
2012  
2013  
2014  
2015  
2016  
2017  
2018  
2019  
2020  
2021  
2022  
2023  
2024  
2025  
2026  
2027  
2028  
2029  
2030  
2031  
2032  
2033  
2034  
2035  
2036  
2037  
2038  
2039  
2040  
2041  
2042  
2043  
2044  
2045  
2046  
2047  
2048  
2049  
2050  
2051  
2052  
2053  
2054  
2055  
2056  
2057  
2058  
2059  
2060  
2061  
2062  
2063  
2064  
2065  
2066  
2067  
2068  
2069  
2070  
2071  
2072  
2073  
2074  
2075  
2076  
2077  
2078  
2079  
2080  
2081  
2082  
2083  
2084  
2085  
2086  
2087  
2088  
2089  
2090  
2091  
2092  
2093  
2094  
2095  
2096  
2097  
2098  
2099  
2100  
2101  
2102  
2103  
2104  
2105  
2106  
2107  
2108  
2109  
2110  
2111  
2112  
2113  
2114  
2115  
2116  
2117  
2118  
2119  
2120  
2121  
2122  
2123  
2124  
2125  
2126  
2127  
2128  
2129  
2130  
2131  
2132  
2133  
2134  
2135  
2136  
2137  
2138  
2139  
2140  
2141  
2142  
2143  
2144  
2145  
2146  
2147  
2148  
2149  
2150  
2151  
2152  
2153  
2154  
215

R<sub>f</sub> 0.7 (5% Et<sub>3</sub>N/EtOAc); Elemental analysis: calculated (0.3H<sub>2</sub>O) C, 71.02, H, 6.96, N, 5.26; found C, 71.20, H, 6.45, N, 5.14. <sup>1</sup>H-NMR (CDCl<sub>3</sub>) δ 1.2-3.5 (m, 24H), 2.85 (s, 2H), 3.02 (s, 3H), 3.42 (s, 3H), 6.85-7.0 (m, 2H), 7.1-7.7 (m, 32H).

5

EXAMPLE 30: N-[(2-((3'-N'-Propyl-(1''R)-3''α-(4-fluorophenyl)tropane-2''β-methoxymethylcarbamoyl)(2-mercaptoethyl)amino)acetyl)-2-aminoethanethiolato]rhenium (V) oxide

(Compound **22** (Re: R=4-F), FIG. 5) (O-1451)

10 N-[2-(3'-N'-propyl-(1''R)-3'' α-(4-fluorophenyl)tropane-2''β-(methoxymethylcarbamoyl))(2-((triphenylmethyl)thio)ethyl)amino)acetyl]-S-(triphenyl)-2-aminoethanethiol **21** (21 mg, 0.02 mmol) in EtOH (4 mL) was heated to reflux. A solution of SnCl<sub>2</sub> (8.4 mg, 0.04 mmol) in 0.005 M HCl (0.5 mL) was added quickly followed immediately by NaReO<sub>4</sub> (13 mg, 0.04 mmol) in 0.005 M HCl (0.5 mL). The solution was refluxed  
15 for 10h and was then loaded onto 0.5 g silica and pumped overnight. The silica-adsorbed material was applied to a chromatography column (3 g SiO<sub>2</sub>, eluent 30% EtOAc/hexanes/5% Et<sub>3</sub>N). Like fractions were combined and concentrated to yield as a purple foam (3.7 mg; 26%).

20 R<sub>f</sub> 0.5 (25% hexanes in EtOAc); <sup>1</sup>H-NMR (CDCl<sub>3</sub>) δ 1.1-4.2 (m, 30H), 4.5-4.6 (m, 1H), 4.75, 5.12 (2d, J=16.7Hz, 2x 6β, 1H), 6.8-7.0 (m, 2H), 7.1-7.2 (m, 2H).



EXAMPLE 31: 2 $\beta$ -Methoxymethylcarbamoyl-3 $\beta$ -(4-fluorophenyl)nortropane  
(Compound **20A** (R=4-F), FIG. 5)

2 $\beta$ -(1-Propanoyl)-3 $\beta$ -(4-fluorophenyl)tropane (143 mg, 0.50 mmol) was combined with 1-chloroethyl chloroformate (2 mL) and the solution was heated to reflux for 2h. The excess chloroformate was removed in vacuo and the residue was refluxed in methanol (30 mL) for 45 min. The methanol was removed in vacuo and the residue was dissolved in CHCl<sub>3</sub> and NaHCO<sub>3</sub>/Na<sub>2</sub>CO<sub>3</sub> (pH=9). The aqueous layer was extracted CHCl<sub>3</sub> (3 x 10 mL) and the combined organic extracts were dried (Na<sub>2</sub>SO<sub>4</sub>), filtered and concentrated. The residue was chromatographed (10-20% Et<sub>3</sub>N in EtOAc). Like fractions were combined to yield 80 mg (58%).

<sup>1</sup>H-NMR (CDCl<sub>3</sub>)  $\delta$  1.50 (m, 1H), 1.7 (m, 2H), 1.95-2.22 (m, 2H), 2.5 (ddd, 1H), 2.92 (s, 3H), 3.1-3.4 (m, 2H), 3.3 (s, 3H), 3.6 (m, 1H), 3.72 (m, 1H), 6.9-7.0 (m, 2H), 7.1-7.3 (m, 2H).

EXAMPLE 32: N-[2-(3'-N'-Propyl-(1''R)-3'' $\beta$ -(4-fluorophenyl)tropane-2'' $\beta$ -methoxymethylcarbamoyl)((2-((triphenylmethyl)thio)ethyl)-amino)acetyl]-S-(triphenyl)-2-aminoethanethiol  
(Compound **21A** (R=4-F), FIG. 5)

2 $\beta$ -(1-Propanoyl)-3 $\beta$ -(4-fluorophenyl)nortropane (80 mg, 0.28 mmol) was combined with MAMA'-Cl (244 mg, 0.32 mmol), KI (84 mg, 0.5 mmol, 2.0 eq.), and K<sub>2</sub>CO<sub>3</sub> (322 mg, 2.3 mmol) in anhydrous MeCN (10 mL) and brought to reflux overnight then cooled to room temperature. The solvent was removed under vacuum

and the residue was applied to a chromatography column (5% Et<sub>3</sub>N in EtOAc). Fractions containing the product were combined and concentrated to yield the product as a light yellow foam (80 mg, 29%).

5 R<sub>f</sub> 0.65 (5% Et<sub>3</sub>N in EtOAc); <sup>1</sup>H-NMR (CDCl<sub>3</sub>) δ 1.2-3.1 (m, 28H), 3.37 (m, 1H), 3.51 (s, 3H), 3.55 (m, 1H), 6.9-7.0 (m, 2H), 7.1-7.5 (m, 32H).

EXAMPLE 33: N-((2-((3'-N'-Propyl-(1''R)-3''β-(4-fluorophenyl)tropane-2''β-methoxymethylcarbamoyl)(2-mercaptoethyl)amino)acetyl)-2-aminoethanethiolato]rhenium (V) oxide

(Compound **22A** (Re: R=4-F), FIG. 5) (O-1451)

10 N-[2-(3'-N'-propyl-(1''R)-3''β-(4-fluorophenyl)tropane-2''β-methoxymethylcarbamoyl)((2-((triphenylmethyl)thio)ethyl)amino)acetyl]-S-(triphenyl)-2-aminoethanethiol (22 mg, 0.02 mmol) in EtOH (10 mL) was heated to reflux. A solution of  
15 SnCl<sub>2</sub> (8.4 mg, 0.05 mmol) in 0.005 M HCl (1.0 mL) was added quickly followed immediately by NaReO<sub>4</sub> (13 mg, 0.05 mmol) in 0.005 M HCl (0.5 mL). The solution was refluxed for 10h and was then applied to a chromatography column (65% EtOAc/hexanes/5% Et<sub>3</sub>N). Like fractions were combined and concentrated to yield a foam (10 mg; 65%).

20

R<sub>f</sub> 0.44 (5% Et<sub>3</sub>N, 30% hexanes in EtOAc); <sup>1</sup>H-NMR (CDCl<sub>3</sub>) δ 1.5-4.2 (m, 30H), 4.4-4.6 (m, 1H), 4.72, 5.05 (2d, J=16.5Hz, 1H), 6.8-7.0 (m, 2H), 7.1-7.3 (m, 2H).

EXAMPLE 34: (1*R*)-*N*-Methyl-2-hydroxymethyl-3-(4-fluorophenyl)-8-azabicyclo[3.2.1]oct-2-ene (Compound **38** (R=4-F), FIG. 9) (O-1337)

(1*R*)-*N*-Methyl-2-methoxycarbonyl-3-(4-fluorophenyl)-8-azabicyclo[3.2.1]oct-2-ene **3** (500 mg, 1.82 mmol) was dissolved in benzene (15 mL) and LAH (70 mg, 1.82 mmol) was added. The reaction was heated to 60 °C overnight. The reaction was cooled to 0 °C, and water (70 µL), 15% NaOH (70 µL), water (200 µL) were added. The reaction was stirred for 15 min and then the salts were filtered off through a pad of celite. The filtrate was dried over Na<sub>2</sub>SO<sub>4</sub> filtered and concentrated to yield **38** (454 mg, 90%) which was purified by column chromatography (30 g SiO<sub>2</sub>; eluent: 4% Et<sub>3</sub>N in 10% MeOH/CHCl<sub>3</sub>). Like fractions were combined, reduced and pumped at high vacuum overnight to yield **38** (336 mg, 74%).

Mp. 106.6-108.7 °C; R<sub>f</sub> 0.2 (10% MeOH/CHCl<sub>3</sub>; 5% Et<sub>3</sub>N); <sup>1</sup>H-NMR (CDCl<sub>3</sub>) δ 1.5-1.7 (m, 1H), 1.9-2.0 (m, 3H), 2.1-2.3 (m, 2H), 2.4 (s, 3H), 2.72 (brd, J=18 Hz, 1H), 3.31 (br s, 1H), 3.55 (d, J=4.1 Hz, 1H), 3.89 (d, J=12.3Hz, 1H), 4.02 (d, J=12.3 Hz, 1H), 6.9-7.0 (m, 2H), 7.1-7.2 (m, 2H). Elemental analysis: calculated C, 72.85, H, 7.34, N, 5.66; found C, 72.94, H, 7.33, N, 5.73.

EXAMPLE 35: (1*R*)-*N*-Methyl-2-hydroxymethyl-3-(3,4-dichlorophenyl)-8-azabicyclo[3.2.1]oct-2-ene (Compound **38** (R=3,4-Cl<sub>2</sub>), FIG. 9)

(1*R*)-*N*-Methyl-2-methoxycarbonyl-3-(3,4-dichlorophenyl)-8-azabicyclo[3.2.1]oct-2-ene **3** (508 mg, 1.56 mmol) was dissolved in benzene (20 mL) and LAH (62 mg, 1.56 mmol) was added. The reaction was heated to reflux overnight. The reaction was cooled to 0 °C, and water (80 µL), 10% KOH (90 µL), water (300 µL) were added.

The reaction was stirred for 15 min and then the salts were filtered off through a pad of celite. The filtrate was dried over Na<sub>2</sub>SO<sub>4</sub> filtered and concentrated to yield a yellow foam (420 mg, 90%) and purified by column chromatography (3% Et<sub>3</sub>N/ 7% MeOH in CHCl<sub>3</sub>) to give 280 mg (60%).

5

R<sub>f</sub> 0.2 (5% MeOH/CHCl<sub>3</sub>; 3% Et<sub>3</sub>N); <sup>1</sup>H-NMR (CDCl<sub>3</sub>) δ 1.5-1.66 (m, 1H), 1.84-1.98 (m, 2H), 2.0 (m, 2H), 2.08-2.24 (m, 2H), 2.39 (s, 3H), 2.7 (dd, 1H), 3.3 (m, 1H), 3.54 (d, J=5.5Hz, 1H), 3.89 (d, J=11.8Hz, 1H), 4.01 (d, J=11.8Hz, 1H), 6.99 (dd, 1H), 7.25 (d, 1H), 7.37 (d, 1H).

10

EXAMPLE 36: (1*R*)-*N*-Methyl-2-carbonyl-3-(4-fluorophenyl)-8-azabicyclo[3.2.1]-oct-2-ene (compound **39** (R=4-F), FIG. 9)

15

A solution of (COCl)<sub>2</sub> (55 mg, 40 μL, 0.43 mmol) and CH<sub>2</sub>Cl<sub>2</sub> (2 mL) was cooled to -78°C and DMSO (65 μL) was added dropwise over 3 min. The reaction was stirred for a further 5 min at -78°C and compound **38** (90 mg, 0.36 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (2 mL) was added dropwise over 10 min. After a further 20 min, Et<sub>3</sub>N (250 μL, 1.80 mmol) was added over 30 min. The reaction was stirred for a further 10 min and then allowed to warm to room temperature. CH<sub>2</sub>Cl<sub>2</sub> (20 mL) and 1M NaOH was added, the layers partitioned and the aqueous layer was washed with CH<sub>2</sub>Cl<sub>2</sub> (1 x 15 mL).

20

Combined organic extracts were dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, concentrated and pumped at high vacuum. The yellow oil obtained (86 mg) was purified by column chromatography (4.5g SiO<sub>2</sub>; 30% EtOAc/hexanes/5% Et<sub>3</sub>N) and like fractions were combined, concentrated and dried at high vacuum to yield the product **39** (62 mg,

63%).

R<sub>f</sub> 0.2 (20% EtOAc/hexane, 5% Et<sub>3</sub>N); <sup>1</sup>H-NMR (CDCl<sub>3</sub>) δ 1.55-1.65 (m, 1H), 1.72-1.82 (m, 2H), 2.14-2.3 (m, 2H), 2.40 (s, 3H), 2.9-3.0 (m, 1H), 3.36-3.44 (m, 1H), 4.02-4.30 (m, 1H), 7.0-7.1 (m, 2H), 7.16-7.24 (m, 2H), 9.45 (s, 1H).

EXAMPLE 37: (1*R*)-*N*-Methyl-2-carbonyl-3-(3,4-dichlorophenyl)-8-azabicyclo[3.2.1]oct-2-ene (Compound **39** (R=3,4-Cl<sub>2</sub>), FIG. 9)

A solution of (COCl)<sub>2</sub> (125 mg, 87 μL, 1.0 mmol) and CH<sub>2</sub>Cl<sub>2</sub> (20 mL) was cooled to -78°C and DMSO (150 μL) was added dropwise over 3 min. The reaction was stirred for a further 5 min at -78°C and compound **38** (245 mg, 0.82 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (5 mL) was added dropwise over 7 min. After a further 30 min, Et<sub>3</sub>N (600 μL, 4.0 mmol) was added over about 15 min. The reaction was stirred for a further 10 min. and then allowed to warm to room temperature. CH<sub>2</sub>Cl<sub>2</sub> (20 mL) and Na<sub>2</sub>CO<sub>3</sub> (20 mL; 1M) was added, the layers partitioned and the aqueous layer was washed with CH<sub>2</sub>Cl<sub>2</sub> (1 x 20 mL). Combined organic extracts were dried Na<sub>2</sub>SO<sub>4</sub>, filtered, concentrated and pumped at high vacuum. The residue was purified by column chromatography (25g SiO<sub>2</sub>; 60% EtOAc/hexanes/5% Et<sub>3</sub>N) and like fractions were combined, concentrated and dried at high vacuum to yield the product **39** (154 mg, 63%).

R<sub>f</sub> 0.2 (75% EtOAc/hexane, 5% Et<sub>3</sub>N); <sup>1</sup>H-NMR (CDCl<sub>3</sub>) δ 1.5-1.7 (m, 1H), 1.7-1.85 (m, 1H), 2.1-2.3 (m, 2H), 2.38 (s, 3H), 2.93 (dd, 1H), 3.39 (m, 1H), 4.05 (dd, 1H), 7.08

(dd, 1H), 7.34 (d, 1H), 7.46 (d, 1H), 9.45 (s, 1H).

EXAMPLE 38: (1*R*)-*N*-Methyl-2-(2-hydroxypropyl)-3-(4-fluorophenyl)-8-aza-bicyclo[3.2.1]oct-2-ene (Compound **40** (R=4-F), FIG. 9)

5 Compound **39** (62 mg, 0.26 mmol) was dissolved in anhydrous THF at room temperature and EtMgBr/Et<sub>2</sub>O (3M; 900  $\mu$ l) was added dropwise. The reaction was stirred at room temperature for 20 min and then at 65°C overnight, and then added slowly to a mixture of 1M HCl (50 mL) and Et<sub>2</sub>O (50 mL) at 0°C. The mixture was basified with saturated aq. Na<sub>2</sub>CO<sub>3</sub> and separated. The aqueous layer was extracted  
10 with CHCl<sub>3</sub> (2 x 20 mL), dried (Na<sub>2</sub>SO<sub>4</sub>), filtered, evaporated and dried at high vacuum. The residue (90 mg) was purified by column chromatography (6 g SiO<sub>2</sub>; 5% Et<sub>3</sub>N/EtOAc) and like fractions were combined, evaporated and dried at high vacuum to yield **40** (82 mg, 52 %).

15 R<sub>f</sub> 0.4 (10% MeOH/CHCl<sub>3</sub>/5% Et<sub>3</sub>N); <sup>1</sup>H-NMR (CDCl<sub>3</sub>)  $\delta$  0.83 (t, J=7.6 Hz, 3H), 1.4-1.7 (m, 4H), 1.81 (d, J=18Hz, 1H), 2.0 (m, 1H), 2.1-2.3 (m, 2H), 2.42 (s, 3H), 2.7 (m, 1H), 3.3 (m, 1H), 3.53 (m, 1H), 4.1-4.2 (m, 1H), 6.9-7.1 (m, 4H)

20 EXAMPLE 39: (1*R*)-*N*-Methyl-2-(2-hydroxypropyl)-3-(3,4-dichlorophenyl)-8-aza-bicyclo[3.2.1]oct-2-ene (Compound **40** (R=3,4-Cl<sub>2</sub>), FIG. 9)

Compound **39** (150 mg, 0.5 mmol) was dissolved in anhydrous THF (25 mL) at room temperature and EtMgBr/Et<sub>2</sub>O (3M; 350  $\mu$ l, 1.05 mmol) was added dropwise over 2 min. The reaction was stirred at room temperature for 2.75h and then added

slowly to a mixture of 1M HCl (20 mL) and Et<sub>2</sub>O (20 mL). The mixture was basified with saturated aq. Na<sub>2</sub>CO<sub>3</sub> and separated. The aqueous layer was extracted with CHCl<sub>3</sub> (3 x 20 mL) dried (Na<sub>2</sub>SO<sub>4</sub>), filtered, evaporated and dried at high vacuum. The residue (197 mg) was purified by column chromatography (20 g SiO<sub>2</sub>; 5%

5 Et<sub>3</sub>N/EtOAc) and like fractions were combined, evaporated and dried at high vacuum to yield **40** (109 mg, 66%).

R<sub>f</sub> 0.07 (5% Et<sub>3</sub>N, 20% hexane in EtOAc); <sup>1</sup>H-NMR (CDCl<sub>3</sub>) δ 0.85 (t, J=7.4 Hz, 3H), 1.4-1.7 (m, 4H), 1.79 (d, J=17.6 Hz, 1H), 1.95-2.1 (m, 1H), 2.1-2.3 (m, 2H), 2.42 (s, 3H), 2.68 (dd, J=4, 18 Hz, 1H), 3.3 (m, 1H), 3.38 (d, 1H), 3.52 (d, J=5 Hz, 1H), 4.1-4.2 (m, 1H), 6.94 (dd, 1H), 7.20 (dd, 1H).

EXAMPLE 40: (1R)-2-Propanoyl-3-(4-fluorophenyl)-8-azabicyclo[3.2.1]-oct-2-ene (Compound **26** (R=4-F), FIG. 9)

15 Tropane **40** (28 mg, 0.1 mmol) in CH<sub>2</sub>Cl<sub>2</sub> was added dropwise to a cold (-78°C) solution of (COCl)<sub>2</sub> (5.5 μL, 0.12 mmol) and DMSO (20 μL, 0.26 mmol) in CH<sub>2</sub>Cl<sub>2</sub>. After stirring for 30 min at -78°C, Et<sub>3</sub>N (75 μL, 0.5 mmol) was added and the reaction was warmed to room temperature. CH<sub>2</sub>Cl<sub>2</sub> and 1M NaOH were added and the layers separated. The organic layer was dried (Na<sub>2</sub>SO<sub>4</sub>), filtered and evaporated and the product applied to a chromatography column (5% Et<sub>3</sub>N, 25% hexane, 70% EtOAc) to 20 give 18.6 mg of product (66%).

R<sub>f</sub> 0.2 (5% Et<sub>3</sub>N, 25% Hexanes, 70% EtOAc); <sup>1</sup>H-NMR (CDCl<sub>3</sub>) δ 0.80 (t, 3H), 1.6 (m,

1H), 1.8-2.3 (m, 6H), 2.40 (s, 3H), 2.75 (dd, 1H), 3.35 (m, 1H), 3.73 (m, 1H), 7.0 (m, 2H), 7.05-7.15 (m, 2H).

EXAMPLE 41: (1*R*)-2-Methoxycarbonyl-3-(4-fluorophenyl)-8-norazabicyclo[3.2.1]-  
5 oct-2-ene (Compound **29** (R=4-F), FIG. 7) (O-1131)

2-Methoxycarbonyl-3-(4-fluorophenyl)tropene **3** (362 mg, 1.3 mmol) was combined with 1-chloroethyl chloroformate (1 mL) and the solution was heated to reflux for 2h. The excess chloroformate was removed in vacuo and the residue was refluxed in methanol (30 mL) for 45 min. The methanol was removed in vacuo and  
10 the residue was dissolved in CHCl<sub>3</sub> and NaHCO<sub>3</sub>/Na<sub>2</sub>CO<sub>3</sub> (pH=9). The aqueous layer was extracted CHCl<sub>3</sub> (3 x 10 mL) and the combined organic extracts were dried (Na<sub>2</sub>SO<sub>4</sub>), filtered and concentrated. The residue was chromatographed (eluent: 1-3% Et<sub>3</sub>N in EtOAc + 0.5% NH<sub>4</sub>OH). Like fractions were combined to yield a yellow solid (234 mg, 68%).

15 R<sub>f</sub> 0.7 (10% MeOH in hexanes + 0.5% NH<sub>4</sub>OH); mp. 67-68 °C; <sup>1</sup>H-NMR (CDCl<sub>3</sub>) δ 1.50-3.0 (m, 6H), 3.8 (m, 1H), 4.2 (m, 1H), 6.8-7.2 (m, 4H). Elemental analysis: calculated C, 68.95, H, 6.17, N, 5.36; found C, 68.81, H, 6.24, N, 5.40.

20 EXAMPLE 42: (1*R*)-2-Methoxycarbonyl-3-(3,4-dichlorophenyl)-8-norazabicyclo[3.2.1]oct-2-ene (Compound **29** (R=3,4-Cl<sub>2</sub>), FIG. 7) (O-1130)

2-Methoxycarbonyl-3-(3,4-dichlorophenyl)tropene (200 mg, 0.61 mmol) was combined with 1-chloroethyl chloroformate (4 mL) and the solution was heated to



reflux for 2h. The excess chloroformate was removed in vacuo and the residue was refluxed in methanol (30 mL) for 45 min. The methanol was removed in vacuo and the residue was dissolved in  $\text{CHCl}_3$  and  $\text{NaHCO}_3/\text{Na}_2\text{CO}_3$  (pH=9). The aqueous layer was extracted  $\text{CHCl}_3$  (3 x 10 mL) and the combined organic extracts were dried (Na<sub>2</sub>SO<sub>4</sub>), filtered and concentrated. The residue was chromatographed (eluent: 5-15% Et<sub>3</sub>N in EtOAc). Like fractions were combined to yield a yellow oil.

R<sub>f</sub> 0.3 (10% Et<sub>3</sub>N in EtOAc); <sup>1</sup>H-NMR (CDCl<sub>3</sub>) δ 1.50-2.3 (m, 5H), 2.5-2.9 (m, 1H), 3.53 (s, 3H), 3.8 (m, 1H), 4.2 (m, 1H), 6.9 (dd, 1H), 7.2 (dd, 1H), 7.4 (d, 1H). Elemental analysis: calculated C, 57.71, H, 4.84, N, 4.49; found C, 57.45, H, 4.87, N, 4.47.

EXAMPLE 43: N-[2-(3'-N'-Propyl-(1''R)-3''-(4-fluorophenyl)trop-2-ene-2''-(methoxycarbonyl))((2-((triphenylmethyl) thio)ethyl)amino)acetyl]-S-(triphenyl)-2-aminoethanethiol (Compound **30** (R=4-F), FIG. 7)

2-(1-Methoxycarbonyl)-3-(4-fluorophenyl)nortrop-2-ene (134 mg, 0.5 mmol) was combined with MAMA'-Cl (387 mg, 0.5 mmol), KI (85 mg, 0.5 mmol), and K<sub>2</sub>CO<sub>3</sub> (707 mg, 5 mmol) in anhydrous MeCN (10 mL) and brought to reflux overnight then cooled to room temperature. The solvent was removed under vacuum and the residue was applied to a chromatography column (1-6% Et<sub>3</sub>N in EtOAc). Fractions containing the product were combined and concentrated to yield the product as a light yellow foam (148 mg, 29%).

R<sub>f</sub> 0.18 (10% Et<sub>3</sub>N in hexane); <sup>1</sup>H-NMR (CDCl<sub>3</sub>) δ 1.3-3.15 (m, 22H), 3.2-3.4 (m, 1H),

3.5 (s, 3H), 3.8-3.9 (m, 1H), 6.8-7.8 (m, 34H).

EXAMPLE 44: N-[2-(3'-N'-Propyl-(1''R)-3''-(3,4-dichlorophenyl)trop-2-ene-2''-(methoxycarbonyl)((2-((triphenylmethyl) thio)ethyl)amino)acetyl]-S-(triphenyl)-2-aminoethanethiol (Compound **30** (R=3,4-Cl<sub>2</sub>), FIG. 7)

2-(1-Methoxycarbonyl)-3-(3,4-dichlorophenyl)nortrop-2-ene (107 mg, 0.34 mmol) was combined with MAMA'-Cl (258 mg, 0.34 mmol), KI (57 mg, 0.34 mmol), and K<sub>2</sub>CO<sub>3</sub> (472 mg, 3.4 mmol) in anhydrous MeCN (10 mL) and brought to reflux overnight then cooled to room temperature. The solvent was removed under vacuum and the residue was applied to a chromatography column (1-6% Et<sub>3</sub>N in EtOAc). Fractions containing the product were combined and concentrated to yield the product as a foam (111 mg, 31%).

R<sub>f</sub> 0.18 (5% Et<sub>3</sub>N in hexane); <sup>1</sup>H-NMR (CDCl<sub>3</sub>) δ 1.4-3.2 (m, 22H), 3.2-3.4 (m, 1H), 3.5 (s, 3H), 3.8-3.9 (m, 1H), 6.8-7.6 (m, 33H).

EXAMPLE 45: N-[(2-((3'-N'-Propyl-(1''R)-3''-(4-fluorophenyl)trop-2-ene-2''-methoxycarbonyl)(2-mercaptoethyl)amino)acetyl)-2-aminoethanethiolato]rhenium (V) oxide (Compound **31** (Re: R=4-F), FIG. 7) (O-1135)

A solution of N-[2-(3'-N'-propyl-(1''R)-3''-(4-fluorophenyl)trop-2-ene-2''-(methoxycarbonyl)(2-((triphenylmethyl) thio)ethyl)amino)acetyl]-S-(triphenyl)-2-aminoethanethiol (130 mg, 0.13 mmol) in EtOH (10 mL) was heated to reflux. A solution of SnCl<sub>2</sub> (28 mg, 0.15 mmol) in 0.005 M HCl (1.0 mL) was added quickly

followed immediately by NaReO<sub>4</sub> (40 mg, 0.15 mmol) in 0.005 M HCl (0.5 mL). The solution was refluxed for 10 h and was then applied to a chromatography column (1-10% Et<sub>3</sub>N in EtOAc). Like fractions were combined and concentrated to yield a foam (34 mg; 37%).

5

R<sub>f</sub> 0.09 (10% Et<sub>3</sub>N in EtOAc); <sup>1</sup>H-NMR (CDCl<sub>3</sub>) δ 1.4-4.3 (m, 23H), 3.5 (s, 3H), 4.5-4.9 (m, 2H), 6.9-7.2 (m, 4H). Elemental analysis: calculated C, 41.49, H, 4.50, N, 6.05; found C, 41.77, H, 4.44, N, 5.93. Accurate mass calculated 696.1348, found 696.1405.

10

EXAMPLE 46: N-[(2-((3'-N'-Propyl-(1''R)-3''-(3,4-dichlorophenyl)trop-2-ene-2''-methoxycarbonyl)(2-mercaptoethyl)amino)acetyl)-2-aminoethane-thiolato]rhenium (V) oxide (Compound **31** (Re: R=3,4-Cl<sub>2</sub>), FIG. 7) (O-1136)

15

A solution of N-[2-(3'-N'-propyl-(1''R)-3''-(3,4-dichlorophenyl)trop-2-ene-2''-(methoxycarbonyl)(2-((triphenylmethyl) thio)ethyl)amino)acetyl]-S-(triphenyl)-2-aminoethanethiol (100 mg, 0.1 mmol) in EtOH (10 mL) was heated to reflux. A solution of SnCl<sub>2</sub> (20 mg, 0.1 mmol) in 0.005 M HCl (1.0 mL) was added quickly followed immediately by NaReO<sub>4</sub> (29 mg, 0.11 mmol) in 0.005 M HCl (0.5 mL). The solution was refluxed for 10h and was then applied to a chromatography column (1-10% Et<sub>3</sub>N in EtOAc). Like fractions were combined and concentrated to yield a foam (56 mg; 78%).

20

R<sub>f</sub> 0.09 (10% Et<sub>3</sub>N in EtOAc); <sup>1</sup>H-NMR (CDCl<sub>3</sub>) δ 1.4-4.2 (m, 23H), 3.55 (s, 3H), 4.4-4.9 (m, 2H), 6.95 (dd, 1H), 7.2 (d, 1H), 7.4 (d, 1H). Elemental analysis: calculated C, 38.65, H, 4.05, N, 5.63; found C, 38.91, H, 3.96, N, 5.57. Accurate mass calculated 746.0663, found 746.0689.

5

EXAMPLE 47: *N*-[2-(3'-*N*'-Propyl-(1"*R*-3"β-(4-fluorophenyl)-2"β-methoxycarbonyltropane))((2-((triphenylmethyl)thio)ethyl)amino)acetyl]-2-aminoethanethiol (Compound **33** (R=4-F), FIG. 8)

To a solution of nor-3β-(4-fluorophenyl)-2β-methoxycarbonyltropane (52.6 mg, 0.2 mmol) in dry acetonitrile (10 mL) was added in succession *N*-[2-((3-chloropropyl)-(2-((triphenylmethyl)thio)ethyl)amino)acetyl]-*S*-(triphenylmethyl)-2-aminoethanethiol (151 mg, 0.2 mmol), KI (33 mg, 0.2 mmol), and K<sub>2</sub>CO<sub>3</sub> (280 mg, 2.0 mmol). The resulting slurry was then boiled overnight. Once the reaction was complete then the solution was allowed to cool to room temperature and then 2 g of silica gel was added and the solvent evaporated. The resulting solid was layered onto a silica gel column and eluted with 0.5% NH<sub>4</sub>OH in 1:1 solution of EtOAc and hexanes. The title compound was recovered as a foam in 72 % yield (141 mg). This was converted to the dihydrochloride.

20 Mp. 166-168°C; IR (KBr) 1666 cm<sup>-1</sup>; <sup>1</sup>H-NMR (CDCl<sub>3</sub>) δ 1.8-3.8, (m, 24H), 3.3 (s, 3H), 3.9-4.0 (m, 1H), 4.2-4.3 (m, 1H), 4.4-4.5 (m, 1H), 6.9-7.4 (m, 34 H). Elemental analysis: calculated (2 HCl • 2 H<sub>2</sub>O): C, 68.24, H, 6.47, N, 3.85. Found: C, 38.03, H, 6.40, N, 3.82.

EXAMPLE 48: (RS)-N-[2-((3'-N'-Propyl-(1''R-3''β-(3,4-dichlorophenyl)-2''β-methoxycarbonyltropane)))(2-mercaptoethyl)amino)acetyl]-2-aminoethanethiol (Compound **33** (R=3,4-Cl<sub>2</sub>), FIG. 8) (O-863)

Prepared identically to the compound in Example 47 above.

5

Mp. 108°C, IR (KBr) 1724, 1653, 957 cm<sup>-1</sup>; <sup>1</sup>H-NMR (CDCl<sub>3</sub>) δ 1.5-3.9 (m, 22H), 3.55 & 3.50 (2s, 3H), 3.9-4.2 (m, 2H), 4.5-4.7 (m, 1H), 4.80 (d, 16.4 Hz, 1H), 7.0-7.4 (m, 3H); Accurate mass calculated for C<sub>24</sub>H<sub>33</sub>Cl<sub>2</sub>N<sub>3</sub>S<sub>2</sub>O<sub>4</sub>Re [MH]<sup>+</sup> 748.0819, found 748.0856. Elemental analysis: calculated, C, 38.55, H, 4.31, N, 5.62. Found C, 38.79, H, 4.38, N, 5.41.

10

EXAMPLE 49: (RS)-N-[2-((3'-N'-Propyl-(1''R-3''β-(4-fluorophenyl)-2''β-methoxycarbonyltropane)))(2-mercaptoethyl)amino)acetyl]-2-aminoethane thiolato]rhenium (V) oxide  
(Compound **34** (Re: R=4-F), FIG. 8) (O-861)

15

N-[2-((3'-N'-Propyl-3''β-(4-fluorophenyl)tropane-2''β-carboxylic acid methyl ester)(2-((triphenylmethyl)thio)ethyl)amino)acetyl]-S-(triphenylmethyl)-2-aminoethanethiol (98 mg, 0.1 mmol) were dissolved in boiling ethanol (1.5 mL). To this was added a solution of SnCl<sub>2</sub> (21 mg, in 200 mL of 0.05 M HCl), followed immediately by a solution of NaReO<sub>4</sub> (30 mg in 200 mL of 0.05 M HCl). Boiling was continued overnight, after which boiling CH<sub>3</sub>CN (10 mL) was added and the resulting solution filtered through a pad of celite. The cake was further washed two more times with boiling CH<sub>3</sub>CN (2 x 20 mL). To the filtrate was added silica gel (1 g) and the

20

solvent evaporated. The solid was then layered onto a silica gel column and eluted with EtOAc. The title compound was isolated as a mixture of diastereomers in 90 % yield (608 mg).

5 Mp 101.9 °C, IR (KBr) 1720, 1666, 957  $\text{cm}^{-1}$ ;  $^1\text{H-NMR}$  ( $\text{CDCl}_3$ )  $\delta$  1.4-4.2, (m, 24H), 3.46 & 3.5 (2s, 3H), 4.4-4.7 (m, 1H), 4.80 & 4.82 (2d, 16 Hz, 1H), 6.8-7.3 (m, 4H); Accurate mass calculated for  $\text{C}_{24}\text{H}_{34}\text{FN}_3\text{S}_2\text{O}_4\text{Re}$   $[\text{MH}]^+$  698.1505, found 698.1557. This was converted to a hydrochloride for analysis: Elemental analysis: calculated ( $\text{HCl} \cdot 2 \text{H}_2\text{O}$ ) C, 37.47, H, 4.98, N, 5.46. Found C, 37.45, H, 4.95, N, 5.40.

10  
EXAMPLE 50: *(RS)-N*-[2-((3'-*N*'-Propyl-(1"*R*-3'' $\beta$ -(3,4-dichlorophenyl)-2'' $\beta$ -methoxycarbonyltropane))(2-mercaptoethyl)amino)acetyl)-2-aminoethane thiolato]rhenium (V) oxide  
(Compound **34** (Re: R=3,4-Cl<sub>2</sub>), FIG. 8) (O-863)

15 Prepared identically to the compound in Example 49 above.

Mp. 108°C, IR (KBr) 1724, 1653, 957  $\text{cm}^{-1}$ ;  $^1\text{H-NMR}$  ( $\text{CDCl}_3$ )  $\delta$  1.5-3.9 (m, 22H), 3.55 & 3.50 (2s, 3H), 3.9-4.2 (m, 2H), 4.5-4.7 (m, 1H), 4.80 (d, 16.4 Hz, 1H), 7.0-7.4 (m, 3H); Accurate mass calculated for  $\text{C}_{24}\text{H}_{33}\text{Cl}_2\text{N}_3\text{S}_2\text{O}_4\text{Re}$   $[\text{MH}]^+$  748.0819, found  
20 748.0856. Elemental analysis: calculated, C, 38.55, H, 4.31, N, 5.62. Found C, 38.79, H, 4.38, N, 5.41.

EXAMPLE 51: (1*R*)-2β-Methoxycarbonyl-3α-(3,4-dichlorophenyl)-8-aza-bicyclo[3.2.1]octane (Compound **35** (R=3,4-Cl<sub>2</sub>), FIG. 8)

(1*R*)-N-Methyl-2β-methoxycarbonyl-3α-(3,4-dichlorophenyl)-8-azabicyclo[3.2.1]-octane **12** (375 mg, 1.14 mmol) and α-chloroethyl chloroformate (ACE-Cl) (3 mL) were  
5 combined and heated at 100 °C (oil bath temperature) for 1h. Excess ACE-Cl was then removed under reduced pressure, and methanol (50 mL) was added to the residue. The mixture was then heated at reflux for 30 min and then concentrated to dryness. The residue obtained was dissolved in CH<sub>2</sub>Cl<sub>2</sub> (75 mL), washed with  
aqueous NH<sub>4</sub>OH, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated to afford the crude  
10 demethylated product. Purification by flash chromatography (1% NH<sub>4</sub>OH, 50-0% hexanes, 50-90% EtOAc 0-10% methanol) gave 250 mg (70%) of **35**.

R<sub>f</sub> 0.14, (5% Et<sub>3</sub>N/EtOAc/hexanes 1:1); <sup>1</sup>H-NMR (CDCl<sub>3</sub>) δ 1.1-2.5 (m, 8H), 2.9-3.3 (m, 1H), 3.5-3.8 (m, 1H), 3.6 (s, 3H), 6.95-7.40 (m, 3H).

EXAMPLE 52: (1*R*)-2β-Methoxycarbonyl-3α-(4-fluorophenyl)-8-azabicyclo[3.2.1]-octane (Compound **35** (R=4-F), FIG. 8)

(1*R*)-N-Methyl-2β-methoxycarbonyl-3α-(4-fluorophenyl)-8-azabicyclo[3.2.1]-octane (95 mg, 0.34 mmol) and ACE-Cl (7 mL) were combined and heated at 100°C (oil  
20 bath temperature) for 1h. Excess ACE-Cl was then removed under reduced pressure, and methanol (50 mL) was added to the residue. The mixture was then heated at reflux for 30 min and then concentrated to dryness. The residue obtained was dissolved in CH<sub>2</sub>Cl<sub>2</sub> (75 mL), washed with aqueous NH<sub>4</sub>OH, dried over Na<sub>2</sub>SO<sub>4</sub>,

filtered, and concentrated to afford the crude demethylated product. Purification by flash chromatography (0-5% NH<sub>4</sub>OH, 10% MeOH in EtOAc) gave 86 mg (95%) of **35**.

R<sub>f</sub> 0.66, (10% MeOH/EtOAc + 0.5% NH<sub>4</sub>OH); <sup>1</sup>H-NMR (CDCl<sub>3</sub>) δ 1.2 (ddd, 1H), 1.2-

5 2.8 (m, 5H), 3.3-3.6 (m, 2H), 3.5 (s, 3H), 3.8-4.2 (m, 2H), 6.9-7.3 (m, 4H).

EXAMPLE 53: N-[2-(3'-N'-Propyl-(1''R)-3''α-(3,4-dichlorophenyl)-2''β-methoxy-carbonyltropane))((2-((triphenylmethyl) thio)ethyl)amino)acetyl]-S-(triphenyl)-2-aminoethanethiol (Compound **36** (R=3,4-Cl<sub>2</sub>), FIG. 8)

10 To a solution of (1R)-2β-methoxycarbonyl-3α-(3,4-dichlorophenyl)-8-azabicyclo [3.2.1]octane **35** (250 mg, 0.79 mmol) in dry CH<sub>3</sub>CN (40 mL) was added in succession N-[[[2-[2-(triphenylmethyl) thio]ethyl](N'-3'-chloropropyl)amino]acetyl]-S-(triphenyl-methyl)-2-aminoethanethiol (601 mg, 0.79 mmol), KI (132 mg), and K<sub>2</sub>CO<sub>3</sub> (1.1 g).  
15 The resulting slurry was maintained at reflux overnight. Once the reaction was complete, the solution was allowed to cool to room temperature and then partitioned between concentrated aqueous NH<sub>4</sub>OH and CH<sub>2</sub>Cl<sub>2</sub>. The layers were separated and the organic phase dried with Na<sub>2</sub>SO<sub>4</sub>. The solution was filtered and concentrated and the residue purified by flash chromatography (15 g, SiO<sub>2</sub>; 0-5% Et<sub>3</sub>N in a 1:1 mixture of EtOAc/hexanes) which gave 100 mg (12%) of a white foam.

20 R<sub>f</sub> 0.26 (2.5% NH<sub>4</sub>OH in EtOAc/hexanes 1/1); <sup>1</sup>H-NMR (CDCl<sub>3</sub>) δ 1.20-1.54 (m, 5H), 1.80-2.50 (m, 15H), 2.81 (d, J=17Hz, 1H), 2.88 (d, J=17Hz, 1H), 3.00 (m, 2H), 3.16-3.40 (m, 3H), 3.54 (s, 3H), 7.03 (dd, J=2.2, 8.5Hz, 1H), 7.14-7.53 (m, 32H). Elemental



analysis: calculated, C, 72.07, H, 6.15, N, 4.07, Cl, 6.86; found C, 72.18, H, 6.21, N, 3.97, Cl, 6.75.

EXAMPLE 54: N-[2-(3'-N'-Propyl-(1''R)-3'' $\alpha$ -(4-fluorophenyl)-2'' $\beta$ -methoxy-carbonyl-tropane))((2-((triphenylmethyl) thio)ethyl)amino)acetyl]-S-(triphenyl)-2-aminoethanethiol (Compound **36** (R=4-F), FIG. 8)

To a solution of (1R)-2 $\beta$ -methoxycarbonyl-3 $\alpha$ -(4-fluorophenyl)-8-azabicyclo [3.2.1]octane **35** (230 mg, 0.87 mmol) in dry CH<sub>3</sub>CN (25 mL) was added in succession N-[[[2-[2-(triphenylmethyl) thio]ethyl](N'-3'-chloropropyl)amino]acetyl]-S-(triphenyl-methyl)-2-aminoethanethiol (660 mg, 0.87 mmol), KI (145 mg, 0.87 mmol), and K<sub>2</sub>CO<sub>3</sub> (1.21 g, 8.7 mmol). The resulting slurry was then maintained at reflux overnight. Once the reaction was complete, the solution was allowed to cool to room temperature and then partitioned between concentrated aqueous NH<sub>4</sub>OH and CH<sub>2</sub>Cl<sub>2</sub>. The layers were separated and the organic phase dried with Na<sub>2</sub>SO<sub>4</sub>. The solution was filtered and concentrated and the residue purified by flash chromatography (50% EtOAc/hexanes + 1% NH<sub>4</sub>OH) which gave 435 mg (51%) of a foam.

R<sub>f</sub> 0.45 (1% Et<sub>3</sub>N, 50% EtOAc, 49% hexanes); <sup>1</sup>H-NMR (CDCl<sub>3</sub>)  $\delta$  1.20 1.3 (m, 1H), 1.3-2.5 (m, 19H), 2.81 (d, J=17 Hz, 1H), 2.86 (d, J=17 Hz, 1H), 2.95-3.05 (m, 2H), 3.10-3.4 (m, 3H), 3.50 (s, 3H), 6.89-6.96 (m, 2H), 7.1-7.5 (m, 32H). Elemental analysis: calculated (0.75 H<sub>2</sub>O), C, 74.78, H, 6.63, N, 4.22; found C, 74.80, H, 6.64, N, 4.17.

EXAMPLE 55: N-[(2-((3'-N'-Propyl-(1''R)-3'' $\alpha$ -(4-fluorophenyl)-2'' $\beta$ -methoxy-carbonyltropane)(2-mercaptoethyl)amino)acetyl)-2-amino-ethanethiolato]-rhenium (V) oxide

5 (Compound **37** (R=4-F), FIG. 8) (O-1186)

A solution of N-[2-(3'-N'-propyl-(1''R)-3'' $\alpha$ -(4-fluorophenyl)-2'' $\beta$ -methoxy-carbonyltropane)(2-((triphenylmethyl) thio)ethyl)amino)acetyl]-S-(triphenyl)-2-aminoethane-thiol (226 mg, 0.23 mmol) in EtOH (10 mL) was heated to reflux. A solution of SnCl<sub>2</sub> (48 mg, 0.25 mmol) in 0.05 M HCl (1.0 mL) was added quickly followed immediately by NaReO<sub>4</sub> (69 mg, 0.25 mmol) in 0.05 M HCl (0.5 mL). The solution was refluxed for 10 h and was then applied to a chromatography column (5% Et<sub>3</sub>N in Et<sub>2</sub>O). Like fractions were combined and concentrated to yield a foam (33 mg; 21%).

15 R<sub>f</sub> 0.38 (10% Et<sub>3</sub>N in EtOAc); <sup>1</sup>H-NMR (CDCl<sub>3</sub>)  $\delta$  0.9-4.3 (m, 24H), 3.53, 3.56 (2s, 3H), 4.4-4.7 (m, 1H), 4.75, 5.00 (2s, 1H), 6.8-7.4 (m, 4H). Elemental analysis: calculated (2/7 Et<sub>2</sub>O) C, 42.06, H, 5.03, N, 5.85; found C, 42.08, H, 4.93, N, 5.85.

EXAMPLE 56: N-[(2-((3'-N'-Propyl-(1''R)-3'' $\alpha$ -(3,4-dichlorophenyl)-2'' $\beta$ -methoxy-carbonyltropane)(2-mercaptoethyl)amino)acetyl)-2-aminoethane-thiolato]-rhenium (V) oxide (compound **37** (R=3,4-Cl<sub>2</sub>), FIG. 8)

20 (O-1196)

Prepare identically to the compound in Example 55.

R<sub>f</sub> 0.51 (10% Et<sub>3</sub>N/EtOAc); <sup>1</sup>H-NMR (CDCl<sub>3</sub>) δ 1.2-1.4 (m, 1H), 1.4-2.5 (m, 11H), 2.89 (m, 1H); 3.10-3.40 (m, 5H), 3.56 & 3.60 (2s, 3H), 3.6-3.8 (m, 0.5H), 3.90-4.15 (m, 3.5H), 4.60 (m, 1H), 4.73 & 4.95 (2d, J = 16.2 & 16.2Hz, 2 x 0.5H), 7.0-7.1 (m, 1H),  
5 7.24-7.36 (m, 2H). Elemental analysis: calculated (H<sub>2</sub>O), C, 37.64, H, 4.48, N, 5.49; found C, 37.59, H, 4.31, N, 5.55.

EXAMPLE 57: (1*R*)-N-Methyl-2-methoxycarbonyl-3-(2-naphthyl)-8-aza-bicyclo[3.2.1]oct-2-ene (Compound **50**, FIG. 10)

10 (1*R*)-2-(Methoxycarbonyl)-3-[[[(trifluoromethyl)sulfonyl]oxy] trop-2-ene **2** (500 mg, 1.52 mmol), LiCl (142 mg, 3.34 mmol), Pd<sub>2</sub>dba<sub>3</sub> (56 mg, 0.06 mmol), Na<sub>2</sub>CO<sub>3</sub> (2.0 M solution in water, 2 mL), diethoxymethane (6 mL) were all charged to a flask and stirred vigorously. To this solution was added 2-naphthyl boronic acid (340 mg, 1.97 mmol). The reaction was then brought to reflux for two hours and then filtered  
15 through celite. The cake was washed with ether and all the organic solution was washed with concentrated ammonium hydroxide solution. The washed solvent was dried with potassium carbonate, filtered, and evaporated. The residue was charged to a column (1-4% Et<sub>3</sub>N/EtOAc) and gave 240 mg (51%) of compound **50**.

20 R<sub>f</sub> 0.48 (10% Et<sub>3</sub>N/EtOAc). <sup>1</sup>H-NMR (CDCl<sub>3</sub>) δ 1.3-3.6 (m, 7H), 2.5 (s, 3H), 3.45 (s, 3H), 3.8-4.0 (m, 1H), 7.2-8.0 (m, 7H). Elemental analysis: calculated (0.5 H<sub>2</sub>O) C, 77.24, H, 6.94, N, 4.50; found C, 77.27, H, 6.94, N, 4.48.

EXAMPLE 58: (1*R*)-2-Methoxycarbonyl-3-(2-naphthyl)-8-azabicyclo[3.2.1]-  
oct-2-ene (Compound **51**, FIG. 10)

(1*R*)-*N*-Methyl-2-methoxycarbonyl-3-(2-naphthyl)-8-azabicyclo[3.2.1]-  
oct-2-ene **50** (100 mg, 0.33 mmol) was combined with ACE-Cl (0.25 mL) and the  
5 solution was heated to reflux for 5h. The excess chloroformate was removed in vacuo  
and the residue was refluxed in methanol for 45 min. The methanol was removed in  
vacuo and the residue was dissolved in CH<sub>2</sub>Cl<sub>2</sub> and shaken with NaHCO<sub>3</sub>/Na<sub>2</sub>CO<sub>3</sub>  
(pH=9). The aqueous layer was extracted CH<sub>2</sub>Cl<sub>2</sub> (4 x 10 mL) and the combined  
organic extracts were dried (Na<sub>2</sub>SO<sub>4</sub>), filtered and concentrated. The residue was  
10 chromatographed (1-10% Et<sub>3</sub>N/EtOAc). Like fractions were combined to yield  
compound **51** (27 mg, 28%).

R<sub>f</sub> 0.15 (10% Et<sub>3</sub>N/EtOAc); <sup>1</sup>H-NMR (CDCl<sub>3</sub>) δ 1.6-2.5 (m, 5H), 2.7-3.1 (m, 1H), 3.45  
(s, 3H), 3.8-3.9 (m, 1H), 4.2-4.35 (m, 1H), 7.1-8.0 (m, 7H).

EXAMPLE 59: N-[2-(3'-*N'*-Propyl-(1''*R*)-2''-methoxycarbonyl-3''-(2-naphthyl)-  
trop-2-ene)](2-(((triphenylmethyl) thio)ethyl)amino)acetyl]-S-  
(triphenyl)-2-aminoethanethiol (Compound **52**, FIG. 10)

To a solution of (1*R*)-2-methoxycarbonyl-3-(2-naphthyl)-8-azabicyclo[3.2.1]-  
20 oct-2-ene **51** (27 mg, 0.09 mmol) in dry CH<sub>3</sub>CN (10 mL) was added in succession N-  
[[[2-[2-(triphenylmethyl) thio]ethyl](*N'*-3'-chloropropyl)amino]acetyl]-S-(triphenyl-  
methyl)-2-aminoethanethiol (70 mg), KI (15 mg), and K<sub>2</sub>CO<sub>3</sub> (127 mg). The resulting  
slurry was maintained at reflux overnight. Once the reaction was complete, the

solution was allowed to cool to room temperature and partitioned between conc. aq. NH<sub>4</sub>OH and CH<sub>2</sub>Cl<sub>2</sub>. The layers were separated and the organic phase dried with Na<sub>2</sub>SO<sub>4</sub>. The solution was filtered and concentrated and the residue purified by flash chromatography (50-90% EtOAc/hexanes + 3% NH<sub>4</sub>OH) which gave 27 mg (29%) of **52**.

R<sub>f</sub> 0.44 (1% NH<sub>4</sub>OH in EtOAc); <sup>1</sup>H-NMR (CDCl<sub>3</sub>) δ 1.5-3.2 (m, 20H), 2.87 (s, 2H), 3.3-3.4 (m, 1H), 3.4 (s, 3H), 3.9-4.0 (m, 1H), 7.0-7.8 (m, 37H).

EXAMPLE 60: N-[(2-((3'-N'-Propyl-(1''R)-2''-methoxycarbonyl-3''-(2-naphthyl)trop-2-ene)(2-mercaptoethyl)amino)acetyl)-2-aminoethane-thiolato]-rhenium (V) oxide (Compound **41**, FIG. 10) (O-1185)

A solution of N-[2-(3'-N'-propyl-(1''R)-2''-methoxycarbonyl-3''-(2-naphthyl)trop-2-ene-))((2-((triphenylmethyl) thio)ethyl)amino)acetyl]-S-(triphenyl)-2-aminoethane-thiol **52** (27 mg, 0.027 mmol) in EtOH (10 mL) was heated to reflux. A solution of SnCl<sub>2</sub> (5.7 mg, 0.03 mmol) in 0.05 M HCl (1.0 mL) was added quickly followed immediately by NaReO<sub>4</sub> (8.2 mg, 0.03 mmol) in 0.05 M HCl (0.5 mL). The solution was refluxed for 10h and was then applied to a chromatography column (5% Et<sub>3</sub>N in Et<sub>2</sub>O). Like fractions were combined and concentrated to yield a mixture of the diastereomers (15 mg; 76%).

R<sub>f</sub> 0.15 (10% Et<sub>3</sub>N in EtOAc); IR (KBr) 967, cm<sup>-1</sup>; Accurate mass calculated:

728.1599, found 728.1664; <sup>1</sup>H-NMR (CDCl<sub>3</sub>) δ 1.3-4.3 (m, 23H), 3.45 (s, 3H), 4.5-4.9

(m, 2H), 7.1-8.0 (m, 7H).

EXAMPLE 61: (1*R*)-N-Methyl-2 $\beta$ -methoxycarbonyl-3 $\beta$ -(2-naphthyl)-8-aza-  
bicyclo[3.2.1]octane (Compound **42**, FIG. 10) (O-1229)

and

(1*R*)-N-Methyl-2 $\beta$ -methoxycarbonyl-3 $\alpha$ -(2-naphthyl)-8-aza-  
bicyclo[3.2.1]octane (Compound **43**, FIG. 10) (O-1228)

To (1*R*)-N-Methyl-2 $\beta$ -methoxycarbonyl-3-(2-naphthyl)-8-azabicyclo[3.2.1]-  
oct-2-ene **50** (510 mg, 1.66 mmol) in THF (15 mL) at -78 °C was added SmI<sub>2</sub> solution  
(0.1 M in THF, 116 mL, 11.6 mmol) dropwise. After 30 min at -78°C MeOH (42 mL)  
was added and the resulting solution stirred at -78 °C for a further hour. The  
reaction was then quenched by adding TFA and water, the cold bath was also  
removed and the solution allowed to attain room temperature. The reaction was then  
made basic with NH<sub>4</sub>OH and diluted with ether and then filtered through celite. The  
filter cake was washed with more ether and then all the organic phases were  
combined and washed with a sodium thiosulfate solution and then a brine solution.  
After drying with sodium sulfate the solution was filtered and concentrated and gave  
the crude products which were isolated by column chromatography (0-2% Et<sub>3</sub>N in  
EtOAc). Compound **42** was isolated as a light yellow solid (110 mg, 22%).

Mp. 94-95 °C. R<sub>f</sub> 0.28 (10% MeOH/CHCl<sub>3</sub>); IR (KBr) 2900, 1750 cm<sup>-1</sup>; <sup>1</sup>H-NMR  
(CDCl<sub>3</sub>)  $\delta$  1.5-2.3 (m, 5H), 2.25 (s, 3H), 2.7 (ddd, 1H), 2.9-3.3 (m, 2H), 3.45 (s, 3H),  
3.3-3.4 (m, 1H), 4.5-4.6 (m, 1H), 7.3-7.5 (m, 3H), 7.7-7.9 (m, 4H). Elemental analysis:

calculated (0.25 H<sub>2</sub>O) C, 76.52, H, 7.55, N, 4.46; found C, 76.63, H, 7.57, N, 4.44.

Compound **43** was isolated as an off-white solid (113 mg, 23%).

5 M.p. 113-114 °C, R<sub>f</sub> 0.56 (10% MeOH/CHCl<sub>3</sub>); IR (KBr) 3000, 1750 cm<sup>-1</sup>; <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 1.4-1.6 (ddd, 1H), 1.4-1.8 (m, 3H), 2.0-2.4 (m, 2H), 2.3 (s, 3H), 2.4-2.7 (m, 1H), 2.65 (dd, 1H), 3.2-3.4 (m, 3H), 3.57 (s, 3H), 7.2-7.5 (m, 3H). Elemental analysis: calculated C, 77.64, H, 7.49, N, 4.53; found C, 77.48, H, 7.50, N, 4.45.

10 EXAMPLE 62: (1*R*)-2β-Methoxycarbonyl-3β-(2-naphthyl)-8-azabicyclo[3.2.1]-octane (Compound **44**, FIG. 10)

(1*R*)-N-Methyl-2β-methoxycarbonyl-3β-(2-naphthyl)-8-azabicyclo[3.2.1]octane **42** (146 mg) was combined with ACE-Cl (5.5 mL) and the solution was heated to reflux for 5h. The excess chloroformate was removed in vacuo and the residue was refluxed in methanol for 45 min. The methanol was removed in vacuo and the residue was dissolved in CH<sub>2</sub>Cl<sub>2</sub> and shaken with NaHCO<sub>3</sub>/Na<sub>2</sub>CO<sub>3</sub> (pH=9). The aqueous layer was extracted CH<sub>2</sub>Cl<sub>2</sub> and the combined organic extracts were dried (Na<sub>2</sub>SO<sub>4</sub>), filtered and concentrated. The residue was chromatographed (2% MeOH/EtOAc). Like fractions were combined to yield **44** (109 mg, 78%).

20 R<sub>f</sub> 0.27 (10% MeOH/EtOAc); <sup>1</sup>H-NMR (CDCl<sub>3</sub>) δ 1.5-2.4 (m, 5H), 2.68 (ddd, 1H), 4.8-4.9 (m, 1H), 3.30 (s, 3H), 3.3-3.4 (m, 1H), 3.7-3.9 (m, 2H), 7.1-8.0 (m, 7H). Elemental analysis: calculated (0.25 H<sub>2</sub>O) C, 76.10, H, 7.23, N, 4.67; found C, 75.98, H, 7.23, N,

4.60.

EXAMPLE 63: (1*R*)-2β-Methoxycarbonyl-3 α-(2-naphthyl)-8-azabicyclo[3.2.1]-  
octane (Compound **45**, FIG. 10)

5 (1*R*)-N-Methyl-2β-methoxycarbonyl-3α-(2-naphthyl)-8-azabicyclo[3.2.1]-  
octane, **43** (90 mg, 0.29 mmol) was combined with ACE-Cl (4 mL) and the solution  
was heated to reflux for 5h. The excess chloroformate was removed in vacuo and the  
residue was refluxed in methanol for 45 min. The methanol was removed in vacuo  
and the residue was dissolved in CH<sub>2</sub>Cl and shaken with NaHCO<sub>3</sub>/Na<sub>2</sub>CO<sub>3</sub> (pH=9).  
10 The aqueous layer was extracted CH<sub>2</sub>Cl and the combined organic extracts were dried  
(Na<sub>2</sub>SO<sub>4</sub>), filtered and concentrated. The residue was chromatographed (2%  
MeOH/CHCl<sub>3</sub>). Like fractions were combined to yield **45** (109 mg, 78%).

R<sub>f</sub> 0.29 (10% MeOH/CHCl<sub>3</sub>).

15 EXAMPLE 64: N-[2-(3'-N'-Propyl-(1''*R*)-2''β-methoxycarbonyl-3''β-(2-naphthyl)-  
tropane)](2-((triphenylmethyl) thio)ethyl)amino)acetyl]-S-  
(triphenyl)-2-aminoethanethiol (Compound **46**, FIG. 10)

To a solution of (1*R*)-2β-methoxycarbonyl-3β-(2-naphthyl)-8-aza-  
20 bicyclo[3.2.1]octane **44** (81 mg, 0.27 mmol) in dry CH<sub>3</sub>CN (20 mL) was added in  
succession N-[[[2-[2-(triphenylmethyl)thio]ethyl](N'-3'-chloropropyl)amino]acetyl]-S-  
(triphenylmethyl)-2-aminoethanethiol (207 mg), KI (46 mg, 0.27 mmol), and K<sub>2</sub>CO<sub>3</sub>  
(378 mg). The resulting slurry was then maintained at reflux overnight. Once the



reaction was complete, the solution was allowed to cool to room temperature and then partitioned between concentrated aqueous  $\text{NH}_4\text{OH}$  and  $\text{CH}_2\text{Cl}_2$ . The layers were separated and the organic phase dried with  $\text{Na}_2\text{SO}_4$ . The solution was filtered and concentrated and the residue purified by flash chromatography (0-90%

5 EtOAc/hexanes + 3%  $\text{NH}_4\text{OH}$ ) which gave 150 mg (54%) of **46**.

$R_f$  0.36 (10%  $\text{Et}_3\text{N}$  in EtOAc);  $^1\text{H-NMR}$  ( $\text{CDCl}_3$ )  $\delta$  1.4-3.8 (m, 24H), 2.85 (s, 2H), 3.38 (s, 3H), 7.0-7.8 (m, 37H).

10 EXAMPLE 65: N-[2-(3'-N'-Propyl-(1''R)-2'' $\beta$ -methoxycarbonyl-3'' $\alpha$ -(2-naphthyl)-tropane)]((2-((triphenylmethyl) thio)ethyl)amino)acetyl]-S-(triphenyl)-2-aminoethanethiol (Compound **47**, FIG. 10)

To a solution of (1R)-2 $\beta$ -methoxycarbonyl-3 $\alpha$ -(2-naphthyl)-8-azabicyclo[3.2.1]octane **45** (17 mg, 0.06 mmol) in dry  $\text{CH}_3\text{CN}$  (10 mL) was added in succession N-[[[2-[2-(triphenylmethyl)thio]ethyl](N'-3'-chloropropyl)amino]acetyl]-S-(triphenylmethyl)-2-aminoethanethiol (4.3 mg), KI (9.4 mg), and  $\text{K}_2\text{CO}_3$  (79 mg). The resulting slurry was then maintained at reflux overnight. Once the reaction was complete, the solution was allowed to cool to room temperature and then partitioned between concentrated aqueous  $\text{NH}_4\text{OH}$  and  $\text{CH}_2\text{Cl}_2$ . The layers were separated and  
15  
20 the organic phase dried with  $\text{Na}_2\text{SO}_4$ . The solution was filtered and concentrated and the residue purified by flash chromatography (50-80% EtOAc/hexanes + 3%  $\text{NH}_4\text{OH}$ ) which gave 18 mg (31%) of **47**.

R<sub>f</sub> 0.16 (50% EtOAc), 47% hexane, 3% NH<sub>4</sub>OH).

EXAMPLE 66: N-[(2-((3'-N'-Propyl-(1''R)-2''β-methoxycarbonyl-3''β-(2-naphthyl)-tropane)(2-mercaptoethyl)amino)acetyl)-2-aminoethanethiolato]-rhenium (V) oxide (Compound **48**, FIG. 10) (O-1339)

A solution of N-[2-(3'-N'-propyl-(1''R)-2''β-methoxycarbonyl-3''-(2-naphthyl)-trop-2-ene)](2-((triphenylmethyl) thio)ethyl)amino)acetyl]-S-(triphenyl)-2-aminoethanethiol **46** (150 mg, 0.15 mmol) in EtOH (10 mL) was heated to reflux. A solution of SnCl<sub>2</sub> (31 mg, 0.16 mmol) in 0.05 M HCl (1.0 mL) was added quickly followed immediately by NaReO<sub>4</sub> (45 mg, 0.16 mmol) in 0.05 M HCl (0.5 mL). The solution was refluxed for 10h and was then applied to a chromatography column (5% Et<sub>3</sub>N in EtOAc). Like fractions were combined and concentrated to yield a mixture of the diastereomers (34 mg; 41%).

R<sub>f</sub> 0.39 (10% Et<sub>3</sub>N in EtOAc); <sup>1</sup>H-NMR (CDCl<sub>3</sub>) δ 1.4-4.2 (m, 24H), 3.40, 3.48 (2s, 3H), 4.4-4.7 (m, 1H), 8.25, 8.30 (2d, 1H), 7.2-8.0 (m, 7H). Elemental analysis: calculated (0.5 EtOAc) C, 46.97, H, 5.30, N, 5.39; found C, 46.91, H, 5.12, N, 5.19.

EXAMPLE 67: N-[(2-((3'-N'-Propyl-(1''R)-2''β-methoxycarbonyl-3''α-(2-naphthyl)-tropane)(2-mercaptoethyl)amino)acetyl)-2-aminoethanethiolato]-rhenium (V) oxide (Compound **49**, FIG. 10)


A solution of N-[2-(3'-N'-propyl-(1''R)-2''β-methoxycarbonyl-3''α-(2-naphthyl)-trop-2-ene)](2-((triphenylmethyl) thio)ethyl)amino)acetyl]-S-(triphenyl)-2-

amino-ethanethiol **47** (18 mg, 0.02 mmol) in EtOH (10 mL) was heated to reflux. A solution of SnCl<sub>2</sub> (5.3 mg) in 0.05 M HCl (1.0 mL) was added quickly followed immediately by NaReO<sub>4</sub> (3.7 mg) in 0.05 M HCl (0.5 mL). The solution was refluxed for 10h and was then applied to a chromatography column (5% Et<sub>3</sub>N in Et<sub>2</sub>O). Like  
5 fractions were combined and concentrated to yield a mixture of the diastereomers (40%).


R<sub>f</sub> 0.46 (5% Et<sub>3</sub>N in EtOAc); <sup>1</sup>H-NMR (CDCl<sub>3</sub>) δ 1.4-1.8 (m, 24H), 1.8-2.0 (m, 2H),  
2.02-2.20 (m, 1H), 2.3-2.5 (m, 3H), 2.69, 2.71 (2s, 3H), 2.9-3.0 (2dd, 1H), 3.1-3.4 (m,  
10 3H), 3.4-3.6 (m, 1H), 3.5, 3.55 (2s, 3H), 3.6-3.8 (2ddd, 1H), 3.9-4.2 (m, 3H), 4.5-4.7 (m,  
1H), 4.75, 4.98 (2d, 1H), 7.32 (d, 1H), 7.3-7.5 (m, 2H), 7.64 (s, 1H), 7.7-7.8 (m, 3H).

#### EXAMPLES 68 - 80


Tests were conducted to determine the binding affinity and selectivity of  
15 certain compounds for the dopamine transporter. The results are tabulated below.




O-1186




O-1196




O-1339




O-1451




O-1505




O-1508




O-1561




O-1136




O-861




O-863



O-927



O-928



O-1185

	Example	Compound	IC50 DAT	IC50 SERT	DAT/ SERT
	68	O-1136	60	1693	28
	69	O-861	2.9	80	28
5	70	O-863	40	-	-
	71	O-927	5.0	200	40
	72	O-928	3.0	30	10
	73	O-1185	63	960	15
	74	O-1186	3.8	1300	340
10	75	O-1196	10	640	64
	76	O-1339	3.6	59	16
	77	O-1451	40	3260	80
	78	O-1505	2.0	497	249
	79	O-1508	5.9	200	34
15	80	O-1561	5.3	337	63

EXAMPLES 81 - 91: <sup>99m</sup>Tc Labeling

The following compounds were prepared by identical methods described below.

20 81 N-[(2-((3'-N'-Propyl-(1''R)-2''β-methoxycarbonyl-3''α-(3,4-dichlorophenyl)-tropane)-(2-mercaptoethyl)amino)acetyl)-2-aminoethanethiolato]-technetium (V) oxide (Compound **37** (R=3,4-Cl<sub>2</sub>), FIG. 8) (O-1196)

82 N-[(2-((3'-N'-Propyl-(1''R)-2''β-1-propanoyl-3''α-(4-fluorophenyl)-tropane)-  
(2-mercaptoethyl)amino)acetyl)-2-aminoethanethiolato]technetium (V) oxide  
(Compound **19** (R=4-F), FIG. 4)

5

83 N-[(2-((3'-N'-Propyl-(1''R)-2''β-1-propanoyl-3''α-(3,4-dichlorophenyl)-  
tropane)(2-mercaptoethyl)amino)acetyl)-2-aminoethanethiolato]-  
technetium (V) oxide (Compound **19** (R=3,4-Cl<sub>2</sub>), FIG. 4)

10

84 N-[(2-((3'-N'-Propyl-(1''R)-2''β-methoxymethylcarbonyl-3''α-(4-  
fluorophenyl)-tropane)(2-mercaptoethyl)amino)acetyl)-2-aminoethanethiolato]-  
technetium (V) oxide (Compound **22** (R=4-F), FIG. 5) (O-1451)

15

85 (RS)-N-[2-((3'-N'-Propyl-(1''R)-2''β-carbomethoxy-3''β-(4-fluorophenyl)-  
tropane))(2-mercaptoethyl)amino)acetyl)-2-aminoethanethiolato]-  
technetium (V) oxide (Compound **34** (R=4-F), FIG. 8)

86 (RS)-N-[2-((3'-N'-Propyl-(1''R)-2''β-carbomethoxy-3''β-(3,4-dichlorophenyl)-  
tropane))(2-mercaptoethyl)amino)acetyl)-2-aminoethanethiolato]-technetium (V)  
oxide (Compound **34** (R=3,4-Cl<sub>2</sub>), FIG. 8)

20

87 N-[(2-((3'-N'-Propyl-(1''R)-2''-carbomethoxy-3''-(4-fluorophenyl)-  
tropene)(2-mercaptoethyl)amino)acetyl)-2-aminoethanethiolato]-  
technetium (V) oxide (Compound **31** (R=4-F), FIG. 7)

88 N-[(2-((3'-N'-Propyl-(1''R)-2''-methoxycarbonyl-3''-(3,4-dichlorophenyl)-  
tropene)(2-mercaptoethyl)amino)acetyl)-2-aminoethanethiolato]-  
technetium (V) oxide (Compound **31** (R=3,4-Cl<sub>2</sub>), FIG. 7)

5 89 N-[(2-((3'-N'-Propyl-(1''R)-2''β-methoxycarbonyl-3''α-(4-fluorophenyl)-  
tropene)(2-mercaptoethyl)amino)acetyl)-2-aminoethanethiolato]-  
technetium (V) oxide (Compound **37** (R=4-F), FIG. 8)

10 90 N-[(2-((3'-N'-Propyl-(1''R)-3''β-(4-fluorophenyl)tropane-2''β-1-propanoyl)-  
(2-mercaptoethyl)amino)acetyl)-2-aminoethanethiolato]technetium (V) oxide  
(Compound **11** (R=4-F), FIG. 3)

15 91 N-[(2-((3'-N'-Propyl-(1''R)-2''β-1-propanoyl-3''β-(3,4-dichlorophenyl)-  
tropane)(2-mercaptoethyl)amino)acetyl)-2-aminoethanethiolato]-technetium (V)  
oxide (Compound **11** (R=3,4-Cl<sub>2</sub>), FIG. 3)

*Deprotection of tropane analog for radiolabeling:*

The following is a description of the procedures that were employed:

20 Twenty microliter aliquots of TFA, CH<sub>2</sub>Cl<sub>2</sub>, and (C<sub>2</sub>H<sub>5</sub>)<sub>3</sub>SiH were added to 5.0  
mg of each trityl protected precursor to cleave the thiol protecting group. After a 20  
min. incubation, 200μL of 1.0 M HCl / Ether was added to protonate the thiols. The  
solvent was evaporated off, followed by successive washes with hexanes to remove the  
trityl groups. The deprotected compound was then dissolved in DMSO to produce a  
stock solution at a concentration of 1 mg/mL.



*Radiolabeling the tropane analog:*

Approximately 200 mCi of sodium  $^{99m}\text{Tc}$  pertechnetate was added to a Glucoheptonate kit (Du Pont Pharmaceuticals, Billerica, MA) and allowed to incubate at room temperature for 15 min. 150 mCi of the resulting  $^{99m}\text{Tc}$ -Glucoheptonate was added to an equal volume of 50 mM Acetate Buffer, pH 5.2 (approximately 2 mL) and 50  $\mu\text{L}$  of deprotected precursor stock solution (1 mg/mL in DMSO, 50  $\mu\text{g}$ ). This solution was incubated at room temperature for 20 min. The course of the radiolabeling was monitored with a Rainin HPLC system using a reverse phase Vydac C8 column (4.6 x 250 mm 5 $\mu\text{m}$ ). The column was eluted with a 0.1M ammonium acetate/acetonitrile mobile phase; 1.5 mL/min. flow rate, and a gradient of 5-100% acetonitrile over 15 minutes. Radioactive detection is achieved with a Frisk - Tech Rate meter (Bicron Corp.). The final radiolabeled product was purified using a C18 Sep-Pak (Waters Inc.) eluted with ethanol. For all compounds, labeling yields and radiochemical purities were greater than 85 % and 98 %, respectively. Each product was diluted with sterile saline to yield a <10% ethanol solution followed by filtration through a 0.22  $\mu\text{m}$  filter prior to injection. Typical HPLC chromatograms are shown in Figures 11 - 14.

*Summary of analytical results, HPLC:*

With the above methodology, it was observed that the retention times were dependent upon two features of the analog, i.e., the conformation and the substituents. As expected the dichloro-analogs eluted later than the monofluorinated compounds and the boat conformers eluted later than the respective chair

compounds. Retention times for four specific  $^{99m}\text{Tc}$  labeled compounds are tabulated below. The reproducibility was  $\pm 0.1$  min.

Example No.	Compound	Retention Time(min.)
Example 82	0-1505T	16.6
Example 90	0-1508T	15.2
Example 83	0-1561T	17.1
Example 91	0-1506T	16.1

*Animal model of Parkinson's disease:*

The neurotoxin MPTP (N-methyl-1,2,3,6-tetrahydropyridine), when administered to monkeys, produces a spectrum of motor, cognitive, biochemical and morphological changes that is not replicated in rodents. MPTP-treated monkeys develop neurological deficits (resting tremor, rigidity, akinesia, postural abnormalities), morphological changes (cell loss in the substantia nigra, ventral tegmental area, retrorubal fields) and biochemical changes (severe depletion of DA and decreases in norepinephrine and serotonin) that closely, parallel idiopathic PD and post-encephalitic Parkinsonism.

Two monkeys were treated with MPTP; 3-5 doses of 0.6 mg/kg administered over 10 days. Treatment was performed under ketamine anesthesia (15 mg/kg). This dose of MPTP, has previously been used to produce Parkinsonism within 2-3 weeks

and depletion of  $^3\text{H}$  or  $^{11}\text{C}$  CFT binding sites by one month. Animals treated in this manner were expected to show an inverse relationship between SPECT tracer binding and motor dysfunction. The marked depletion of DA terminals produced by this treatment should provide definitive evidence of the selectivity and sensitivity of the SPECT tracers to detect full depletion of the nerve terminals.

### *SPECT imaging*

All SPECT images were acquired with a MultiSPECT 2 gamma camera (Siemens, Hoffman Estates, IL) equipped with fan-beam collimators and peaked to the 140 KeV photopeak of  $^{99\text{m}}\text{Tc}$  (15% window). This camera has intrinsic resolution of 4.6 mm (FWHM), and a sensitivity of  $\sim 240$  cps/mCi. Images were acquired over  $360^\circ$  (60 projections / head,  $128 \times 128$  matrix) in the continuous mode. Image reconstruction was performed using a conventional filtered back-projection algorithm to an in-plane resolution of 10 mm FWHM and attenuation correction via the Chang method.

Rhesus monkeys weighing approximately 7 kg were anesthetized with ketamine/xylazine (15.0 and 1.5 mg/kg) and positioned prone on the imaging bed of the SPECT camera. Before the start of imaging, a venous catheter was inserted in a peripheral vein for radiopharmaceutical administration. The heads of the animals were immobilized with a custom fabricated head holder. Approximately 20-25 mCi of  $^{99\text{m}}\text{Tc}$  labeled O-1505T, O-1508T, O-1561T or O-1560T was injected intravenously over 60 seconds. Dynamic SPECT imaging was initiated at the end of the infusion and consisted of 2 min. acquisitions during the first hour and 5 min. acquisitions

thereafter.

*Selectivity of For DAT Sites in the Monkey Brain*

For this study, a monkey was positioned supine on the imaging table of the  
5 MultiSPECT 2 gamma camera and injected with ~20 mCi of  $^{99m}\text{Tc}$  O-1560T as  
described above. At approximately 20 min. after radiopharmaceutical administration,  
the animal was injected with CFT (1.0 mg/kg) and imaging was continued for an  
additional 70 min.

10 *Image analysis*

SPECT slices with greatest striatal activity or in which the occipital cortex was  
well visualized were summed and regions of interest (ROI's) were constructed. In the  
striatal planes, ROI's were placed on the right and left striatum (caudate + putamen).  
Radioactivity in the right and left striatum were averaged. ROI radioactivities  
15 (cpm/cc) were decay corrected to the time of injection. The difference between striatal  
and occipital cortex activity (specific binding) was calculated for each image and was  
plotted as a function of time. Corrections for scattered fraction and partial volume  
effects were not performed.

20 *Radiation dosimetry*

Groups of male Sprague-Dawley rats were injected with ~10 mCi of  $^{99m}\text{Tc}$   
labeled O-1505T and O-1561T. At time intervals between 5 min. and 24 hrs after  
injection, groups of 6 animals injected with each radiopharmaceutical were sacrificed  
and biodistribution was measured. Samples of blood, heart, lung, liver, spleen,

kidney, adrenal, stomach, GI tract, testes, bone, bone marrow and skeletal muscle were weighed and radioactivity was measured with a well type gamma counter (LKB model # 1282, Wallac Oy, Finland). To correct for radioactive decay and permit calculation of the concentration of radioactivity in each organ as a fraction of the administered dose, aliquots of the injected doses were counted simultaneously. The results were expressed as percent injected dose per gram (%I.D./g) and radiation dosimetry was estimated by the MIRdose method.

## RESULTS

*SPECT imaging with <sup>99m</sup>Tc labeled O-1505T, O-1508T, O-1561T and O-1560T*

In the images acquired early after injection of <sup>99m</sup>Tc O-1505T and <sup>99m</sup>Tc O-1561T, diffuse accumulation of radioactivity was observed throughout the brain. Over the first several minutes after injection, accumulation of tracer in the striatum intensified and the level of radioactivity in all other structures decreased. By 30 minutes after injection there was excellent contrast between striatum and the rest of the brain. Trans-axial, sagittal and coronal images of monkey brains were acquired between 30 and 50 minutes after injection of <sup>99m</sup>Tc labeled O-1505T, O-1508T, O-1561T and O-1560T. From these data, it is clear that the images acquired after injection of <sup>99m</sup>Tc O-1505T and <sup>99m</sup>Tc O-1561T (boat forms of the monofluoro and dichloro compounds, respectively) display high concentrations of radiopharmaceutical in the striatum with minimal accumulation in other areas of the brain. In particular, lack of accumulation in the thalamus, hypothalamus or midbrain, regions that are rich in 5-HT transporters, supports the specificity of this tracer for DAT sites. Region of interest analysis yielded striatal to occipital cortex ratios of approximately ~2.5 to 1.

In this experiment, images acquired after injection of  $^{99m}\text{Tc}$  O-1508T and  $^{99m}\text{Tc}$  O-1560T (chair forms of the monofluoro and dichloro compounds, respectively) differed with O-1508T failing to demonstrate significant accumulation of radioactivity in striatum or elsewhere in the brain while O-1560T provided results more like O-1505T and O-1561T.

*SPECT of MPTP treated monkeys*

(Mid-striatal) trans-axial, sagittal and coronal SPECT images of the brain of a rhesus monkey injected with  $^{99m}\text{Tc}$  O-1505T were obtained one month after MPTP treatment. Compared with normal animals, after MPTP treatment, the level of accumulation decreased markedly and the striatum could not be differentiated from surrounding structures.

*Selectivity of  $^{99m}\text{Tc}$  O-1505T for DAT sites in monkey brain*

SPECT images of monkey brain showed significant accumulation of  $^{99m}\text{Tc}$  O-1505T in the striatum. In the early images there was diffuse accumulation of radioactivity throughout the brain. Over the first several minutes after injection, accumulation of tracer in the striatum intensified and the level of radioactivity in all other structures decreased. By 30 minutes after injection there was excellent contrast between striatum and the rest of the brain. After injection of a receptor saturating dose of unlabeled CFT, striatal accumulation of radioactivity decreased and by 60 minutes after injection, there was no evidence of focal accumulation in the striatum.

*Radiation dosimetry*

The biodistribution studies demonstrated that both  $^{99m}\text{Tc}$  O-1505T and  $^{99m}\text{Tc}$  O-1561 cleared rapidly from all tissues of the rat. For  $^{99m}\text{Tc}$  O-1505T, MIRdose calculations revealed urinary bladder to be the target organ with a dose of 0.29 rem/mCi. Total body effective dose was estimated at 0.037 rem/mCi

*Summary:*

These results demonstrate that  $^{99m}\text{Tc}$  labeled O-1505T and O-1561T are excellent SPECT ligands for DAT sites. These radiopharmaceuticals combine the following important characteristics for obtaining useful diagnostic images: (1) high striatal to occipital cortex ratios; (2) high selectivity for DAT vs. 5-HT transporter (SET) sites; (3) convenient preparation at high specific activity and radiochemical purity; (4) favorable radiation dosimetry and (5) striatal localization rate that is well matched to the physical  $t_{1/2}$  of  $^{99m}\text{Tc}$ .

The present invention has been described in detail, including the preferred embodiments thereof. However, it will be appreciated that those skilled in the art, upon consideration of the present disclosure, may make modifications and/or improvements of this invention and still be within the scope and spirit of this invention as set forth in the following claims.